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Objectives: This thesis is aimed to detect the incidence of mood disorders in cancer patients, and 
to assess the role of arthritis and multimorbidity in the development of mood disorders. The thesis 
will also describe the impact of arthritis and mood disorders on the health care utilization of cancer 
patients accounting for the role of other comorbidities.  
Methods: The thesis is a population-based study with linked administrative health databases, 
available from the Institute for Clinical Evaluative Sciences, and included all adult patients 
diagnosed with cancer in Ontario between 2003 and 2013. The study used a retrospective cohort 
design. Univariate and bivariate analyses were used to describe the incidence of mood disorders, 
level of multimorbidity, and characteristics of patients with cancer. Survival analysis was used to 
evaluate the adjusted impact of arthritis and other variables on the occurrence and time to the 
development of mood disorders. Negative binomial regression was performed to assess the 
adjusted effect of arthritis and mood disorders on health service utilization by cancer patients.  
Results: The cumulative crude incidence of mood disorders over the study period in cancer 
patients in Ontario was 16.9 (95% CI 16.6-17.3)/1,000 population. Arthritis was not associated 
with an increased risk of developing mood disorders in crude and adjusted analysis; however, 
multimorbidity significantly increased the risk of mood disorders. Mood disorders and arthritis 
increased health care utilization in cancer patients. The average hospitalizations per person-year 
in patients with mood disorders diagnosed before (0.73± 1.06 ) and after (1.09 ± 1.33) cancer was 
higher than patients without mood disorders (0.57 ± 0.92). Similarly, average ED visits per person-
year were also higher when mood disorders were diagnosed before (1.03 ± 1.68 ) or after (1.20 ± 
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2.10 ) cancer compared to the patients without mood disorders. Arthritis increased only ED visits 
while decreasing hospitalization. When mood disorders and arthritis were both present in patients 
with cancer and diagnosed after cancer there was a 28% (95% CI = 20-37%) higher risk of 
hospitalization and a 60% (95% CI = 50-69%) increased risk of ED visits compared to those 
without any of these conditions. 
Conclusion: The study provided evidence on the risk of developing mood disorders in cancer 
patients with multiple chronic conditions. Multimorbidity is an important risk factor for developing 
mood disorders and the number of chronic conditions rather than a specific condition like arthritis 
increases the likelihood of developing mood disorders. The study showed the importance of 
addressing multimorbidity to improve the mental health outcomes in cancer patients. The findings 
of the study also described the impact of arthritis and mood disorders on the health service 
utilization of cancer patients. Mood disorders increased health services use more than arthritis. 
Early identification of psychological and other chronic conditions may decrease hospital 














Overview of Thesis Content  
      The thesis is organized into seven chapters. Chapter 1 provides a general introduction to the 
topic and includes a discussion of multimorbidity in cancer patients, arthritis, mood disorders, and 
health care utilization. The second chapter is the literature review, synthesizing detailed knowledge 
about the study topics and the possible research gaps. The third chapter is the overview of the 
thesis methodology including the approach to the study, objectives and hypothesis, conceptual 
frameworks, and general methods. Specifically, the fourth and fifth chapters address the main 
objectives in the form of manuscripts for publications. The fourth chapter addresses the first 
objective of the thesis, i.e. the impact of arthritis on the development of mood disorders in cancer 
patients and whether this association varies by the level of multimorbidity. The fifth chapter 
addresses the other objective, i.e. the impact of arthritis and mood disorders on the health care 
utilization of cancer patients while considering the number of other comorbid conditions. The sixth 
chapter is comprised of the general study findings with a brief discussion of the epidemiological 
aspects with the strengths and limitations of the thesis. The seventh and final chapter describes the 






































     Non-communicable diseases are becoming the greatest group of health concerns in the world 
and responsible for the majority of global death (World Health Organization, 2018). This includes 
cancer, one of the leading causes of death internationally, and particularly in developed countries 
(Bray et al., 2018). One in two Canadians is at risk of developing cancer in his or her lifetime 
(Canadian Cancer Society, 2017), and one in every four Canadians is expected to die from the 
disease (Canadian Cancer Society, 2018). In Ontario, the number of newly diagnosed malignant 
cancers in 2018 was 90,483; this equates to an age-standardized incidence of 571.1 cases per 
100,000 people (Cancer Care Ontario, 2018). The survival of cancer patients has been increased 
markedly over the decades in Canada. Ellison (2018) reported that the median increase in 5-year 
net cancer survival was 6.9-8.6% between the ages of 15 to 74 years within the last twenty years 
(Ellison, 2018). 
     People with cancer are also often faced with the co-occurrence of multiple chronic conditions, 
or multimorbidity (MMB). In Canada, among the general population, 25% or more individuals 
aged above 40 years have MMB, and MMB is even higher in the elderly population (Feely et al., 
2017; Koné Pefoyo et al., 2015). In Ontario, over 75% of cancer patients have at least one 
additional chronic condition (Feely et al., 2017; Koné Pefoyo et al., 2015). MMB is positively 
associated with mortality in older adults, and the risk of death increases with the number of chronic 
conditions (Nunes et al., 2016). MMB in cancer patients results in reduced survival, lower quality 
of life, complexity in treatment, poorer outcomes, and cancer patients with MMB often represent 
high-cost users of the health care system (Lee et al., 2011; Perruccio et al., 2007; Sarfati et al., 
2016; Søgaard et al., 2013; St John et al., 2014). 
    Clustering of chronic conditions with cancer may be due to common risk factors with cancer, 
such as old age, smoking, alcohol, poor diet, lack of physical activities, and obesity (Extermann, 
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2007; Sarfati et al., 2016). Cancer often occurs in combination with musculoskeletal diseases 
(including arthritis), cardiovascular diseases, metabolic diseases (such as hypertension, 
hyperlipidemia, diabetes), and gastrointestinal conditions; mood disorders (such as depression) are 
particularly prevalent in cancer patients (Kenzik et al., 2016; Koné Pefoyo et al., 2015; Massie, 
2004; Roy et al., 2018). Studies have reported the prevalence of depression among cancer patients 
in the range of  20-40%, and at least 15% of cancer survivors have a diagnosis of major depressive 
disorder (MDD) (Lima et al., 2016; Pitman et al., 2018). Polsky et al. (2005) found that patients 
newly diagnosed with cancer were approximately four times more likely to develop depressive 
symptoms compared to the persons having no cancer (Polsky et al., 2005). Another study has 
reported that among cancer patients seeking mental outpatient services, at least 18% have mood 
disorders (Anuk et al., 2019).  
     The prevalence of mood disorders among cancer patients increases with multimorbidity; 
inflammatory conditions characterized by pain like arthritis, cancer, fibromyalgia, and heart 
diseases show associations with mood disorders (Anuk et al., 2019; S. B. Patten et al., 2018; Scott 
B. Patten, 2005). For example, arthritis has been positively linked with mood disorders including 
depression in several research studies (Choy & Calabrese, 2018; Nicassio, 2010; Sturgeon et al., 
2016). A meta-analysis by Sturgeon et al. (2016) has reported that the prevalence of MDD in 
patients with rheumatoid arthritis is 16.8% whereas the lifetime prevalence of MDD among the 
US general population is 7.1% (Sturgeon et al., 2016; National Institute of Mental Health, 2019). 
Cancer diagnosis, pathophysiology, and its treatment, including chemotherapy, are associated with 
the development of mood disorders especially depression (Anuk et al., 2019; Pitman et al., 2018; 
Smith, 2015). Depressive disorders cause physical distress, decreased quality of life, poor 
treatment compliance, thus, negatively impact cancer outcomes and complicates care management 
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(Colleoni et al., 2000; Fitzgerald et al., 2015; Kanani et al., 2016; M. Li et al., 2016; Pinquart & 
Duberstein, 2010). Moreover, patients diagnosed with cancer and depression are likely to have 
more hospital admissions, extended hospital stays, increased number of emergency and primary 
care visits (Mausbach & Irwin, 2017; R. Patel et al., 2018).  
     The occurrence of mood disorders in cancer patients has been addressed in the literature, while 
cancer and musculoskeletal conditions are proved to each be associated with mood disorders. 
However, the effects of arthritis on the development of mood disorders in cancer patients still 
remain unknown. This study will examine the impact of arthritis on the development of mood 
disorders in cancer patients. We will also test the hypothesis that the co-occurrence of arthritis and 
mood disorders increases health services use among cancer patients. We will evaluate the 
combined impact of arthritis and mood disorders on health care utilization among cancer patients 
in terms of hospital admissions and emergency (ED) visits. Although several studies have focused 
on health care utilization (HCU) in cancer patients, this proposed study is novel because we use a 
robust population-based design to determine the influence of MMB, particularly arthritis and mood 





































       The study is intended to describe the impact of arthritis on the development of mood disorders 
in cancer patients as well as how this cluster of comorbidities affects health service utilization. 
Therefore, the review of the literature will be related to the following key concepts relevant to the 
study; cancer, arthritis, multimorbidity, depression, and health care utilization. We conducted a 
literature search to understand the current body of knowledge regarding these topics. PubMed was 
searched in June 2019 and in May 2020 with specific keywords including comorbid*, 
"Comorbidity"[Mesh], "Multimorbidity"[Mesh], MDD [Mesh], Arthritis [Mesh] depress*, 
“Depressive Disorder"[Mesh], malignan*, cancer*, "Neoplasms"[Mesh], “Cancer AND mood 
disorders”, “Arthritis AND mood disorders”, “Cancer AND Hospitalization”, “Cancer AND 
Health care utilization” “Arthritis AND Health care utilization”, “ Mood disorders AND health 
care utilization.” 
     Articles focusing on the prevalence of mood disorders in cancer patients, the impact of mood 
disorders on cancer outcomes, including HCU, and treatment were selected for further review. We 
also included the papers describing multimorbidity (MMB) in cancer patients, including arthritis 
and its impact on the development of mood disorders as well as HCU. The literature review 
provided a detailed description of cancer and its burden, MMB in cancer patients, development of 
mood disorders in cancer patients, the role of arthritis on the development of mood disorders, 
sociodemographic factors, the biological mechanism of cancer, arthritis and mood disorders, and 
the impact of MMB especially arthritis and mood disorders on the utilization of health care services 
by cancer patients. 
2.1 Cancer Burden and Risk Factors 
     “Cancer is a disease where abnormal cells divide without control and can invade nearby tissue. 
Cancer cells can also spread to other parts of the body through the blood and lymph systems” 
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(National Cancer Institute, n.d.). The incidence of cancer is increasing, and in 2018, there were 
18.1 million new cancer cases diagnosed globally compared to 12.7 million in 2008 (Bray et al., 
2018; Jemal et al., 2011). The World Health Organization ranked cancer as the second leading 
cause of death worldwide in 2018, with an estimated 9.6 million deaths attributed to cancer (World 
Health Organization, 2018). Cancer was previously known as the disease of high-income 
countries, although the prevalence is now rising in the low and middle-income countries due to 
aging populations and lifestyle factors (Bray et al., 2018; Torre et al., 2016).  
     In Canada, 225,800 newly diagnosed cancer cases are expected in 2020, of which 83,300 will 
die from the disease (Brenner et al., 2020). There are wide provincial differences in the incidence 
rate of cancer. Eastern Canada comprised of Atlantic Canada, Quebec, and Ontario has a higher 
incidence rate of cancer, while British Columbia continues to have the lowest incidence rate (Xie 
et al., 2015). Within the period 2013-17, the age-specific incidence rate (ASIR) of all cancers 
among males was 392 per 100,000 person-year in British Columbia, whereas, in Atlantic Canada, 
the ASIR was as high as 545 per 100,000 person-year in Prince Edward Island (Xie et al., 2015). 
Cancer is the leading cause of mortality and the seventh most costly illness in Canada (Canadian 
Cancer Society, 2017). According to a recent Canadian Cancer Society report, the 5-year net 
survival for all cancers combined is 63%, and slightly higher for females than males (Canadian 
Cancer Society, 2019). The highest cancer mortality in Ontario in 2018 is attributable to lung, 
colorectal, female breast, and pancreatic cancer (Cancer Care Ontario, 2018). The incidence rate 
and mortality rates are higher in males and people aged 60-79 (Cancer Care Ontario, 2018). It is 
predicted that the healthcare system in Canada will face challenges for the appropriate care 
management of cancer patients in the future (Canadian Cancer Society, 2017). 
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     Cancer can occur in almost any site of the body, such as lung, brain, skin, gastrointestinal tract, 
breast, reproductive organs, kidney, blood, and so on (Bray et al., 2018; Xie et al., 2015). However, 
the most prevalent cancer sites vary substantially by age, sex, and sociodemographic 
characteristics (Bray et al., 2018). In Canada, in 2019, the most frequently occurring cancers 
among males irrespective of age are prostate, lung, colorectal, bladder, and lymphoma, whereas, 
the most prevalent cancers in females are breast, lung, colorectal, uterus, and thyroid (Canadian 
Cancer Society, 2019).  
    Cancer results from a complex interplay between genetic, environmental, and lifestyle factors 
(Wei et al., 2010; Wu et al., 2018). Heredity has been proven to play a role in breast, colon, and 
several childhood cancers (Frank, 2004; Tomasetti & Vogelstein, 2015). Other non-modifiable 
risk factors contributing to the development of cancer include age, male sex, family history, 
ethnicity, and hormones (Wu et al., 2018; Canadian Cancer Society, 2019). A study conducted in 
the Czech Republic describes that among the 80,000 newly diagnosed cancer patients each year, 
the majority are aged 55 years or older (Smetana Jr. et al., 2016). The authors hypothesize that 
aging causes irreversible cellular damage which increases the likelihood of developing cancer 
(Smetana Jr. et al., 2016). According to the Canadian Cancer Society, in the age group 20-59 years, 
females have a higher incidence of cancer, whereas, in all other age groups, males are 
predominantly affected (Canadian Cancer Society, 2017). There is also a racial variation of cancer 
prevalence in Canada; Caucasians have a higher prevalence of cancer (Lebrun, 2011).  
       Smoking is the most important modifiable risk factor for many cancers including lung, 
esophagus, throat, oral, colorectal, larynx, kidney, urinary bladder, liver, pancreas, stomach, 
breast, ovary, and cervix(Gapstur et al., 2018; Y.-S. Sun et al., 2017).  Alcohol, lack of physical 
activity, obesity, and diets deficient in fruits and vegetables are other modifiable risk factors for 
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various cancers including breast, colorectal, prostate, and liver cancer (Gapstur et al., 2018; Key 
et al., 2004; A. Patel et al., 2018; Y.-S. Sun et al., 2017; Tan et al., 2018; Wei et al., 2010). 
Environmental exposures, for example, radiation, carcinogenic chemicals, sunlight, second-hand 
smoking, and certain infections like Human Papilloma Virus (HPV), Human Immuno Deficiency 
Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Helicobactor pylori also 
represent risk factors for developing cancer (Gapstur et al., 2018; Wei et al., 2010; Canadian 
Cancer Society, 2017). Cancer risk factors vary according to sociodemographic characteristics. 
For example, in high-income countries smoking, obesity and alcohol are associated with the 
development of a majority of cancers, whereas, in low and middle-income countries associated 
factors are smoking, deficient diet, and sexually transmitted HPV infection (Danaei et al., 2005).   
2.2 Multimorbidity (MMB) in Cancer Patients 
     Multimorbidity is the presence of multiple diseases in an individual, often defined as the co-
occurrence of two or more diseases (Feely et al., 2017; Johnston et al., 2019; Koné Pefoyo et al., 
2015). MMB is more common among the elderly, females, people from the lower-income 
quintiles, low educational attainment, and Indigenous populations (Kuwornu et al., 2014; Roberts 
et al., 2015; Skivington et al., 2015). In Canada, the prevalence of MMB is around 26%, reaching 
66% for people above 65 years of age (Feely et al., 2017). The highest prevalence is observed for 
asthma, diabetes, hypertension, arthritis, and mood disorders (Lebenbaum et al., 2018; Roberts et 
al., 2015).  
       MMB is common among cancer patients and survivors. A cohort study based on population 
health administrative data in Ontario reports that around 75% of cancer patients have at least two 
conditions and 25% have three or more conditions besides cancer (Koné Pefoyo et al., 2015). Older 
cancer patients are more likely to have comorbid conditions as age is a common risk factor for 
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cancer and MMB (Corbett & Bridges, 2019). Cancers associated with the highest comorbidities 
include prostate, breast, colorectal, and cervical cancer, which may be explained by the longer 
survival rate for these cancer types (Salako et al., 2018). A population-based cross-sectional study 
conducted in Australia reported an increased prevalence of mental/behavioral problems, 
musculoskeletal and circulatory conditions in current cancer patients compared to those without 
cancer (H. Ng et al., 2016). Ayeni et al. (2019) conducted a study on South African breast cancer 
patients and described that the most prevalent co-occurring chronic conditions were obesity (85%), 
hypertension (61%), impaired fasting glucose (47%), and depression (11%) (Ayeni et al., 2019). 
However, the prevalence of mood disorders including adjustment disorder, anxiety, and depression 
is reported to be as high as 38% among cancer patients compared to the global prevalence of 14% 
among the general population (Mitchell et al., 2011; Waraich et al., 2004). 
2.3 Cancer Survival and Impact of Multimorbidity 
     Cancer survival varies by cancer type, clinical stages, as well as sociodemographic, and 
healthcare factors. For example, lung cancer has an extremely poor prognosis, with a median 
survival of one year (Tas et al., 2013). For colorectal cancer, 1-year survival is estimated at 97.7% 
with a diagnosis at stage 1 but falls to 43.9% when diagnosed at stage 4 (Hawkes, 2019). On the 
other hand, breast and prostate cancer have a much higher one and five-year survival. Patients 
diagnosed with stage 1, 2, or 3 prostate cancer have almost 100% one and five-year survival. 
However, if they are diagnosed at stage 4, the one and five-year survival decrease to 87.6% and 
47.7%, respectively (Hawkes, 2019). In Canada, most breast cancers are diagnosed at stage 1, with 
an overall five-year survival of 84-88% (Canadian Cancer Society, 2018).  
     Age, sex, and ethnicity are important predictors of cancer survival (Neal & Allgar, 2005; Tas 
et al., 2013; E. T. Warner et al., 2015). A study conducted on lung cancer patients showed that the 
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one-year survival rate was 67.3% for younger and 42.5% for elderly patients; age remained a 
significant predictor of mortality after controlling for demographic and clinical variables (Tas et 
al., 2013). Another study on breast cancer assessing the role of ethnicity in cancer survival found 
that the black population had 21% more risk of death due to breast cancer compared to Caucasians; 
while Hispanics and Asian people had a 44% lower risk of breast cancer-related death (E. T. 
Warner et al., 2015). Socioeconomic conditions also influence survival for many cancers 
(Bermedo-Carrasco & Waldner, 2016; de Graeff et al., 2001; C. D. Hsu et al., 2017). 
Sociodemographic factors are related to the stage of cancer diagnosis, which may impact the 
survival (Arndt et al., 2001; C. D. Hsu et al., 2017; Neal & Allgar, 2005; Woods et al., 2006).  
       On the other hand, advanced cancer treatment modalities, for instance, chemotherapy, 
radiotherapy, hormonal treatment, immunotherapy, surgery, and early initiation of treatment 
contribute to improving cancer outcomes, survival, and patient’s quality of life (Daneshi et al., 
2018; Glimelius et al., 1996; Kopetz et al., 2009; Miller et al., 2019; Tsai et al., 2018). However, 
cancer and its treatment cause physical and psychosocial sequelae (Miller et al., 2019; Stanton et 
al., 2015); survivors of cancer have compromised physical, mental health, and lower quality of life 
(Stanton et al., 2015). Besides, cancer risk and mortality, as well as needs for resources, increase 
with MMB, the co-existence of multiple chronic conditions (Eibl et al., 2018; Johnson et al., 2016; 
Tu et al., 2018). 
       MMB impacts the timing of cancer diagnosis, complicates treatment with polypharmacy, and 
increases mortality among cancer patients (Sarfati et al., 2016; Cancer Care Ontario, 2018). While 
it is established that early detection leads to better outcomes, studies reported that comorbidities 
can lead to delayed screening procedures among women and increase the odds of late diagnosis of 
breast cancer (Gurney et al., 2015; D. F. Warner et al., 2017). However, one study reported higher 
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odds of screening mammography for breast cancer among women with MMB compared to those 
with no chronic conditions (Koroukian et al., 2018). In a cohort of lung cancer patients, 
comorbidity led to earlier diagnosis owing to frequent physician’s visits (Dima et al., 2018).  
     The survival of cancer patients is influenced by the level of MMB (Dima et al., 2018; Jørgensen 
et al., 2012; Ording et al., 2013). Elderly lung, colorectal, and prostate cancer patients with MMB 
have a higher risk of mortality compared to those without any chronic conditions (Jørgensen et al., 
2012). Besides, cancer patients with MMB have a lower quality of life (Fortin et al., 2004), higher 
functional impairment, and poorer self-reported health compared to those with no additional 
condition (D. F. Warner et al., 2017).  MMB also adds to the treatment burden on cancer patients 
(Salako et al., 2018; Sarfati et al., 2016; Shrestha et al., 2019). Multimorbid cancer patients are 
less compliant with treatment, more prone to develop side-effects, likely to be prescribed multiple 
drugs (polypharmacy), have less access to curative cancer surgery, and become socially isolated 
(Corbett & Bridges, 2019; Ihemelandu et al., 2016; Ritchie et al., 2011). Arthritis is one of the 
most prevalent chronic conditions in cancer patients and it impacts patients’ outcomes and care 
management (Nayak, Luo, Elting, Zhao, & Suarez-Almazor, 2017; Roy et al., 2018) as described 
in the following sections. 
2.4 Arthritis 
       Arthritis is a clinical condition referring to joint disorders and is characterized by pain, 
swelling, and limitation of movement (Health Canada, 2003).  It is a disease of the musculoskeletal 
system involving joints, ligaments, tendons, and bones (Health Canada, 2003). Arthritis causes 
pain, swelling, stiffness in joints, thereby leading to disability and decreased quality of life 
(Arthritis Alliance of Canada, 2011). Arthritis is one of the leading chronic diseases among adults. 
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In Canada, in 2011, 4.4 million adults (13% of the population) were living with osteoarthritis 
(Arthritis Alliance of Canada, 2011). It is estimated that by 2026, 6 million Canadians aged 15 or 
more will suffer from arthritis and related disorder (Health Canada, 2003). Arthritis is more 
common among the elderly, obese, and persons receiving hormone replacement therapy (Health 
Canada, 2003). The population prevalence of rheumatoid arthritis (RA) in Canada was 0.9% in 
2011 and is expected to be 1.3% in the next 30 years (Arthritis Alliance of Canada, 2011). 
      Osteoarthritis (OA) is the most common type of arthritis, and it is particularly prevalent among 
the middle-aged and elderly population (American College of Rheumatology, 2019). OA involves 
the entire joint causing “wear and tear” of the joint structures and the lifetime risk of developing 
the condition is around 46% (American College of Rheumatology, 2019). Rheumatoid arthritis 
(RA) causes joint destruction and occurs in older adults (Helmick et al., 2008). Pain is the primary 
complaint in the majority of patients with arthritis, and levels of pain are twice as high in people 
with arthritis as in the general population  (Health Canada, 2003). In their study on the quality of 
life of RA patients, Corbacho & Dapueto (2010) found that 60% of patients with RA had moderate 
to severe pain, and 70% of patients had some sort of disability (Corbacho & Dapueto, 2010). 
Arthritis causes limitations in daily activities, particularly among the elderly population around 
two-third of the patients with arthritis develop disability (Health Canada, 2003). However, more 
than half of the children with juvenile arthritis in Canada also mentioned problems with performing 
their daily activities (Health Canada, 2003). The patients with arthritis have an inferior self-
reported health status, lower satisfaction while in different social roles, poor employment 
outcomes, and suffer from continuous fatigue, sleep disturbance, and stress (Health Canada, 2003; 
Gignac et al., 2008, 2018).  
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        Risk factors for arthritis vary by the types of arthritis. Risk factors for OA and RA are 
increasing age, female sex, ethnicity, genetic factors, nutrition, obesity, metabolic diseases, 
smoking, osteoporosis, joint injury and decreased muscle function; particularly BMI >30, have 
been associated with 2.81 times higher probability of knee OA (Litwic et al., 2013; Xu & Lin, 
2017). Aging affects joints through the inflammatory process and the majority of the people aged 
65 or more have radiographic features of OA (D. Chen et al., 2017; Litwic et al., 2013).  
     Patients with inflammatory rheumatic conditions are more likely to present with MMB; for 
example, two-third of patients with rheumatoid arthritis have another comorbid condition 
(Filipowicz-Sosnowska, 2019; Radner, 2016). Comorbidities impact the disease course and 
outcomes in arthritic conditions leading to poorer prognosis (Filipowicz-Sosnowska, 2019). 
Literature suggests hypertension, hypercholesterolemia, diabetes, cardiovascular diseases, obesity, 
depression, and cancer as the commonly co-occurring conditions with rheumatic diseases 
(Filipowicz-Sosnowska, 2019; Radner, 2016). On the other hand, arthritis is one of the most 
common comorbidities occurring in cancer patients (Roy et al., 2018). 
2.5 Arthritis and cancer 
     The relationship between cancer and arthritis is complex and multifactorial. Cancer and its 
treatment impact the outcomes of patients with arthritis (Almoallim et al., 2017; Andrykowski et 
al., 1999; Elandt & Aletaha, 2011; Naidoo et al., 2017; D. D. Yang et al., 2018), whereas, in some 
instances, arthritis can be a risk factor for cancer (Askling et al., 2005; Y.-J. Chen et al., 2011; 
Lewis et al., 2018; Mellemkjaer et al., 1996; Rohekar et al., 2008; Wilton & Matteson, 2017). In a 
population-based cohort study, it was found that the risk of Hodgkin and Non-Hodgkin lymphoma, 
lung, and skin cancer was higher among RA patients; however, the risk for colorectal and breast 
cancer was reduced (Mellemkjaer et al., 1996). Hellgren and Colleagues (2010) found a 1.75 times 
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higher risk of lymphoma in RA patients and concluded that inflammation, immunosuppressive 
treatment, genetic, and environmental factors might explain the higher occurrence of cancers in 
patients with RA (Hellgren et al., 2010). In a retrospective population-based cohort study Ward & 
Alehashemi, (2020) found that knee and hip osteoarthritis was related to increased risk of 
melanoma, renal cancer, and cancer of the bladder, breast, uterus, and prostate while lowering the 
risk of the oropharynx, esophagus, stomach, colon/rectum, hepatobiliary, pancreas, larynx, lung, 
and ovarian cancer (Ward & Alehashemi, 2020). However, the risk of specific cancers increased 
with the duration of osteoarthritis (Turkiewicz et al., 2020). Researchers mentioned that lower 
expression of a protein, Chondromodulin-1, might be the link between the pathogenesis of cancer 
and OA (Zhu et al., 2019). 
    The treatment of arthritis may also contribute to the development of cancer. Patients receiving 
cyclophosphamide, a drug used for RA, predispose them to the risk of bladder cancer (Wilton & 
Matteson, 2017). On the other hand, the cancer treatment has been linked to developing arthritis 
by several authors (Almoallim et al., 2017; Andrykowski et al., 1999; Naidoo et al., 2017; D. D. 
Yang et al., 2018).  In a study conducted on prostate cancer patients, researchers found a 23% 
increased risk of developing RA among patients treated with androgen deprivation therapy (D. D. 
Yang et al., 2018). In their review article, Naidoo et al. (2017) described that there might be an 
association between cancer treatment with immune checkpoint blocking and the development of 
post-treatment arthralgia or inflammatory arthritis (Naidoo et al., 2017).   
    The impact of arthritis on cancer outcomes has been addressed in several studies (Ji, Liu, 
Sundquist, & Sundquist, 2011; Nayak et al., 2017). In a large population-based retrospective 
cohort study in the United States, breast cancer patients with two or more claims for RA in the last 
12 months had 41% higher mortality than those without an RA diagnosis  (Nayak et al., 2017). In 
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prostate cancer patients, people with RA had 53% higher mortality considering the disease stage 
and tumor size (Nayak et al., 2017). Another study in Sweden reported similar findings (Ji et al., 
2011); they reported a 31% higher mortality in cancer patients hospitalized with RA compared to 
those without RA. The lowest survival was found in skin, breast cancer, and non-Hodgkin 
lymphoma in patients with RA (Ji et al., 2011). 
     As mentioned above, mood disorders are commonly occurring comorbidities with arthritis, with 
or without cancer, and may also affect the role of arthritis. The relationships between arthritis, 
mood disorders, and cancer are described in detail below.   
2.5.1 The role of arthritis in developing mood disorders 
     The prevalence of mood disorders is 45% among the patients with RA and the prevalence of 
depression is as high as 61% in patients with OA (Leite et al., 2011; Nicassio, 2010). A study 
conducted by He et al. (2008) found that patients with arthritis had 1.9 times higher odds of mood 
disorders compared to the general population (He et al., 2008). Another retrospective cohort study 
revealed that patients with RA had twice the risk of developing bipolar disorder than people 
without RA (Hsu et al., 2014) The risk of depressive symptoms increases with disease severity 
among OA patients (Rathbun et al., 2018). The pain and disability are significantly related to mood 
disorders and among the working population with arthritis pain is a predictor of developing 
depressive symptoms (Li et al., 2006; Nicassio, 2010; Parmelee et al., 2012). However, a recent 
study suggests that arthritis and mood disorders have a shared pathological process as both 
conditions are characterized by inflammation (Vallerand et al., 2019). Arthritis patients with co-
occurring mood disorders are more likely to experience increased pain, disability, and decreased 
activity (Marks, 2014; Sharma et al., 2016; Sturgeon et al., 2016; Tsuchiya et al., 2014). Patients 
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with arthritis and depression are at increased risk of polypharmacy and are high users of health 
services (Sharma et al., 2016; Vergés Milano et al., 2016).  
2.6 Mood Disorders 
     “Mood disorders are psychiatric conditions in which the principal feature is a prolonged 
pervasive emotional disturbance, such as a depressive disorder, bipolar disorder, or substance-
induced mood disorders. The term ‘chronic mood disorders’ is applied when symptoms rarely 
remit” (American Psychiatric Association Dictionary, 2018). According to the World Health 
Organization, around 310 million people were suffering from depression and bipolar disorder 
globally in 2018, which made it one of the significant contributors to the global disease burden 
(World Health Organization, 2018). In Canada, in 2018, around 2,802,000 people were suffering 
from any kind of mood disorder which was 8.9% of the population aged 12 or older (Statistics 
Canada, 2020). The annual prevalence of depression in Canada was 4.7% in 2012, and Canadians 
had a lifetime prevalence of 11.2%. (Knoll & MacLennan, 2017). Among patients with cancer or 
arthritis in Canada, the prevalence of mood disorders in 2005 was 10.1% and 10.9%, respectively 
(Gadalla, 2008). Bipolar disorders are relatively uncommon and a cross-sectional survey 
conducted in 11 countries reports that the lifetime prevalence of developing bipolar disorder is 
2.4% (Rowland & Marwaha, 2018). Another study reported that the prevalence of self-reported 
bipolar disorders was only 0.87% in Canada (McDonald et al., 2015). However, a portion of 
patients diagnosed and treated for major depressive disorders may also have co-occurring bipolar 
disorder (Rybakowski et al., 2005). Mood disorders, particularly depression, are more common 
among people who are females, separated, unemployed, and those with chronic diseases; with the 
peak incidence found in ages15-24 years (Gadalla, 2008; Scott B. Patten et al., 2006). On the other 
hand, bipolar disorders are linked with several genetic and environmental factors, but no 
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significant established environmental and genetic risk factors were found for bipolar disorder 
(Rowland & Marwaha, 2018b).     
2.7 Mood disorders in cancer patients 
    Psychiatric disorders are common among patients with cancer. In a systematic review, the 
authors reported that the prevalence of mental health conditions in cancer patients was around 32% 
(95% confidence interval 27% to 37%) (Singer et al., 2010). Around 97.5% of cancer patients 
attending psychiatric outpatient departments receive a diagnosis of a psychiatric condition and the 
prevalence of mood disorders is as high as 18-29% (Anuk et al., 2019; Mitchell et al., 2011). 
Several studies have reported a higher prevalence of depression among cancer patients than the 
general population (Hartung et al., 2017; Pitman et al., 2018; Yang et al., 2013). A study conducted 
in Germany detected 5.4 times higher odds of depression among cancer patients than the general 
population estimate (Hartung et al., 2017). However, there are substantial variations in the 
prevalence of depression due to the different scales used to quantify depression and depressive 
symptoms (Caruso et al., 2017; Krebber et al., 2014), varying between 10% and 25% for most 
studies (Hartung et al., 2017; Knoll & MacLennan, 2017; Ng et al., 2011; Nikbakhsh et al., 2014; 
Pitman et al., 2018; Walker et al., 2013; Walker et al., 2014), and reaching 76% for patients with 
oesophageal cancer (Chung et al., 2018; Hong & Tian, 2014; Massie, 2004; Shankar et al., 2016; 
Yang et al., 2013). On the other hand, mood disorders, particularly bipolar disorder have been 
associated with an increased risk of cancer (BarChana et al., 2008; Lin et al., 2013). However, 
there is little evidence found in the literature regarding the increased risk of bipolar disorders in 
cancer patients.  
     The development of mood disorders varies by cancer type. For example, patients with cancer 
in the head-neck region have a prevalence of depression as high as 50% (Yadav et al., 2019), and 
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depression is most common among patients with pancreatic, gastric, lung, colorectal, breast, and 
genitourinary cancer (Chung et al., 2018; Massie, 2004; Shankar et al., 2016; Jane Walker et al., 
2014). Major depressive disorder (MDD) is mostly found among cancer patients in palliative care 
(J. Walker et al., 2013), having other psychological or medical conditions (Hartung et al., 2017; 
Massie, 2004) and with late-stage metastatic carcinoma (Hartung et al., 2017).  Caruso et al. (2017) 
conducted a meta-analysis and described that family history of mood disorders, female sex, and 
poor support act as potential risk factors for depressive spectrum disorders in cancer patients 
(Caruso et al., 2017). Breast cancer patients undergoing mastectomy fear a change in their body 
image, and up to 50% of them may develop symptoms of anxiety and mood disorders (Lasry et 
al., 1987; Pan et al., 2016).  Pirl & Roth (1999) performed a systematic review and concluded that 
uncontrolled pain was the primary cause of depression in cancer patients; recognizing the pain and 
attempting to relieve the pain improved depression symptoms in those patients (Pirl & Roth, 1999). 
Alemayehu and colleagues (2018) found a four times higher risk of depression among cancer 
patients who complained of moderate pain and thirteen times higher risk of depression with severe 
pain (Alemayehu et al., 2018). Cancer treatment including medication, chemotherapy, and 
advanced immune therapies are also responsible for causing depressive spectrum disorders 
(Caruso et al., 2017; Scott B. Patten & Barbui, 2004; Pirl & Roth, 1999; Smith, 2015). MMB in 
cancer patients is a predictor of mood disorders. For example, depression is often found in 
combination with neurological, endocrine, and inflammatory diseases (Pirl & Roth, 1999; Smith, 
2015). Literature suggests that cancer causes altered stress response resulting in the alteration of 
neuroendocrine pathways which ultimately lead to the development of depressive spectrum 
disorders (Caruso et al., 2017; Postal & Appenzeller, 2015; Young et al., 2014). 
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    The presence of depression in cancer patients and its association with higher mortality is 
addressed in the literature (Iglay et al., 2017; Pinquart & Duberstein, 2010; Satin et al., 2009). A 
study conducted on breast cancer patients with mood disorders revealed that patients with 
depression had a 1.33 (95% CI: 1.20–1.48) times higher risk of mortality than those without any 
mood disorders but no significant difference in survival was found for the patients with bipolar 
disorders (Kanani et al., 2016). The association between mood disorders particularly depression 
and higher mortality are evident for all cancer sites, including lung, breast, gastrointestinal, and 
other cancer sites (Onitilo et al., 2006). Depression causes late diagnosis of cancer as well as an 
interruption, lower acceptance of, and less response to treatment (Colleoni et al., 2000; J. Lin et 
al., 2016; Pinquart & Duberstein, 2010; Zimmaro et al., 2018). Nielson and colleagues (2019) 
determine that elderly cancer patients with bipolar disorders receive treatment at a later stage, 
impacting their survival (Nielsen et al., 2019). Several other studies also linked bipolar disorders 
with increased mortality in cancer patients (Chang et al., 2014; Kanani et al., 2016).  
    Depression, one of the most prevalent mood disorders has been linked to the quality of life of 
cancer survivors by several authors (Khue et al., 2019; Q. Li et al., 2018; Rolke et al., 2008; Smith, 
2015; Villarreal-Garza et al., 2019). Khue et al. (2019) conducted a study on lung cancer patients 
in Vietnam and revealed that health-related quality of life was significantly lower among those 
who were depressed compared to the patients without depression (Khue et al., 2019). Depression 
raises the tendency of suicide, especially among cancer patients with poor social support (Dauchy 
et al., 2013).  
     The management of mood disorders in cancer patients is complex and requires integrated 
pharmacologic and psychological intervention (M. Li et al., 2016; Mehta & Roth, 2015). Cancer 
patients are sometimes widely prescribed with antidepressants leading to polypharmacy 
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(Desplenter et al., 2012). However, there is also a risk of inadequate treatment in cancer patients 
with depression (Jane Walker et al., 2014). In a population-based study in Denmark, Y. Sun et al. 
(2015) found that treatment of depression with antidepressant drugs caused 32% higher one-year 
and 22% higher five-years mortality (Y. Sun et al., 2015). In cancer patients with bipolar disorders 
or mania, the choice of antipsychotic drugs should be made carefully according to the severity of 
the disease and symptoms; long term use of such drugs may lead to complications (Mehta & Roth, 
2015). 
     In summary, arthritis and mood disorders contribute to worse outcomes, such as lower survival 
and lower quality of life among cancer patients, and the impact may be exacerbated when they are 
both present. Hence, it is important to study and monitor the risk of mood disorders among cancer 
patients for their well-being. A key outcome is the utilization of health services by cancer patients, 
which impacts both the individual and the healthcare system. 
2.8 Health Care Utilization (HCU) 
     Health care service utilization has been modeled in various ways, but the Anderson Behavioral 
Model is one of the most widely used models (Babitsch et al., 2012). A person’s HCU is 
determined by the methods of delivery of the services, changing medical technologies, social 
definition of the disease, and by the individual predisposing, enabling, and need factors (R. 
Andersen & Newman, 2005). HCU is particularly high among males, unmarried patients, persons 
with comorbidities, psychological disorders, persons who smoke or drink alcohol, or have chronic 
pain (Graham et al., 2019). HCU can be measured from two perspectives: quantity and quality (Da 
Silva et al., 2011). Quantitative indicators of  HCU include hospitalization per year, the number of 
patients and visits, whereas the quality indicators include accessibility, continuity, 
comprehensiveness, and productivity of care (Da Silva et al., 2011).  
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2.8.1 Cancer and health care utilization: role of arthritis and mood disorders 
     Cancer patients represent the highest users of the health care system, and many factors 
determine their HCU. In Ontario, approximately one-third of cancer patients had other chronic 
conditions besides cancer, and these represented the top 10% of the health care users (ICES, 2014). 
In a population-based study on data from the Eindhoven Cancer Registry, Mols et al. (2007) 
described that cancer survivors had more general and specialist physicians’ visits than the general 
population. In particular, HCU was highest among Hodgkin’s lymphoma patients and in patients 
with comorbidities (Mols et al., 2007). In cancer patients, the co-occurrence of chronic conditions 
was associated with increased physician’s visit (Arreskov et al., 2018; Duthie et al., 2017; Kent et 
al., 2018). Lash et al. (2017) conducted a systematic review and reported that there was a variation 
in the percentage of cancer patients having at least one ED visit, ranging from 7-12% across the 
studies. ED visits were highest among female reproductive organ cancer patients, followed by 
colorectal, prostate, lung, and breast cancer (Lash et al., 2017). They also found that ED visits 
were more common among cancer patients with African-American ethnicity, advanced age, male 
gender, residing in an urban area, being unmarried, having severe symptoms, stage III or IV cancer, 
comorbidities, and who survived at least one year after cancer diagnosis (Lash et al., 2017).  
       MMB, especially common comorbidities such as arthritis and mood disorders impacts health 
care utilization among cancer patients (Himelhoch et al., 2004; Pitman et al., 2018; Roy et al., 
2018; Wright et al., 2010). In their study, Wright et al. (2010) found that patients with knee 
osteoarthritis had higher health care utilization compared to those without OA, and the HCU 
increased with the presence of comorbidities including cancer (Wright et al., 2010).  
     Several studies have addressed the impact of mood disorders on HCU by cancer patients 
(Himelhoch et al., 2004a; Mausbach & Irwin, 2017; McDermott et al., 2018a; Niazi et al., 2018). 
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Niazi et al. (2018) described that multiple myeloma patients with comorbid mood disorders had 
41% more hospitalizations, 37% higher ED visits, and 22% higher ambulatory service usage than 
patients without mood disorders (Niazi et al., 2018). Patel and colleagues (2018) conducted a study 
on breast, prostate, colorectal, and lung cancer patients in the United States to reveal the impact of 
MDD on patient outcomes. They found that cancer patients with MDD had a significantly higher 
mean hospital stay across all four cancer types (Patel et al., 2018). Cancer patients with pre-existing 
depression have lower odds of inpatient visits, ED visits, and ICU admission than patients without 
depression; however, when depression was diagnosed after cancer, an increase in HCU was found, 
but not statistically significant (McDermott et al., 2018). Although several studies focused on HCU 
by cancer patients, there is still inadequate evidence of the impact of MMB, especially the 
occurrence of arthritis and mood disorders on health service usage among cancer patients in 
Canada. This research will address the impact of arthritis and mood disorders on the HCU of cancer 
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     The literature review suggested that mood disorders are prevalent among cancer patients and 
have a negative impact on cancer outcomes. It is also known that cancer patients with 
multimorbidity are more prone to develop mood disorders, particularly depression. However, the 
combined role of arthritis and MMB on the development of mood disorders in cancer patients is 
still not clearly described, and this thesis is aimed to address those gaps in the literature. 
Understanding the effect of arthritis and MMB on the development of mood disorders will help to 
detect cancer patients most vulnerable to developing psychological morbidities.  
3.1 Objectives 
   The primary objective of this research is to measure the incidence of mood disorders among cancer 
patients in Ontario, Canada, and to assess the associated sociodemographic and clinical factors, 
including multimorbidity and in particular, comorbid arthritis as an example of inflammatory disease, 
associated with mood disorders among people with cancer. This study also aims to evaluate health 
service utilization among cancer patients with multimorbidity, particularly arthritis and mood 
disorders. The specific research questions are- 
1. What is the incidence of mood disorders among cancer patients in Ontario? 
a. Does arthritis increase the risk of mood disorders in cancer patients? 
b. What is the impact of arthritis on the development of mood disorders in cancer patients 
at different levels of multimorbidity? 
2. Do arthritis and mood disorders increase health care utilization in cancer patients? 
a. How does the impact of arthritis and mood disorders on health care utilization among 
cancer patients vary by level of multimorbidity?  
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3.2 Approach to Thesis 
     This study aims to determine the impact of arthritis (exposure) on the development of mood 
disorders (outcome) in cancer patients while accounting for the role of sociodemographic factors 
and the level of multimorbidity.  In the second part of the study, we looked at the role of arthritis 
and mood disorders (exposures) on the health service utilization among cancer patients in terms of 
hospitalizations and emergency (ED) visits (outcomes) considering the level of multimorbidity. A 
quantitative study with health administrative data in Canada was designed to answer the research 
questions. The conceptual framework of this study was based on Andersen’s Behavioral Model of 
Health Services Use (R. M. Andersen, 1995). The model suggests that HCU is a function of several 
predisposing, enabling, and need factors (R. M. Andersen, 1995). The predisposing factors 
determine the likelihood that people will need the health care system and include social structures 
like education, occupation, ethnicity, social interactions, culture or health beliefs, or demographic 
variables such as age and sex (R. M. Andersen, 1995). The enabling factors are the people’s and 
community’s capability and resources for using the health care system. These factors are 
comprised of personal/family factors like health insurance, knowledge of access to care, traveling 
or community factors, or genetic and psychological attributes (R. M. Andersen, 1995). The need 
factors are either perceived by the patients arising from the symptoms of the disease and pain or 
evaluated needs based on professional judgment. The need factors raise people’s demand for health 
care (R. M. Andersen, 1995).  
      For the proposed project, predisposing factors included age, sex, and ethnic concentration. The 
enabling factors were income and the place of residence (rural/urban), while chronic conditions, 
namely cancer, arthritis, and mood disorders acted as the health care need factors.  
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Hypothesis#1: Arthritis increases the risk of mood disorders among cancer patients and the 
presence of other comorbidities exacerbates the risk. 
 
                    
 
                                                                     
 
Fig 1: Impact of arthritis on the development of mood disorders considering the 
sociodemographic and clinical factors 
Hypothesis#2: Arthritis and mood disorders increase the health care utilization (hospitalizations 
and ED visits) among cancer patients; the co-occurrence of other comorbid conditions further 
increases HCU. 
 
                                           
                 
 
       
Fig 2: Impact of arthritis and mood disorders on the HCU by cancer patients 
Arthritis in cancer patients                
(Exposure) 
Mood disorders (Outcome) 
Number of other comorbid conditions 
(excluding arthritis) 
Sociodemographic factors: Age, sex, 
ethnicity, income, place of residence 
Clinical factors: Cancer type and stage 
Arthritis and mood 
disorders (Exposures) 
Hospitalization and ED visits 
per person year (Outcomes) 
Number of other comorbid conditions (except arthritis and mood 
disorders), the time of arthritis and mood disorders diagnosis 
Sociodemographic factors: Age, sex, ethnicity, income, place of 
residence 
Clinical factors: Cancer type and stage 
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3.4 Study Design and Population 
    We used a retrospective cohort study based on health administrative data to describe the impacts 
of arthritis and MMB on the development of mood disorders in cancer patients. The design helped 
to determine if a causal relationship exists, and helped validate our assumptions about the 
association between arthritis, MMB, and mood disorders in patients with cancer (Luisa Vázquez 
Navarrete, 2009). All the adult patients diagnosed with cancer in Ontario between 2003-13 without 
pre-existing mood disorders and who survived at least a year after their cancer diagnosis were 
included as the study population. We further performed another retrospective cohort study with 
the same databases and included all the adult patients having cancer between 2003-13 and 
surviving at least a year to evaluate the effect of arthritis and mood disorders on the hospitalization 
and ED visits following cancer diagnosis considering the number of other comorbid conditions.  
3.5 Data Sources 
    This study was based on provincial administrative databases in Ontario that were linked to 
define the study population and outcome of interest. These datasets are housed at the Institute for 
Clinical Evaluative Sciences (ICES) and include information on health services utilization, disease 
registries, and basic population characteristics. All the residents of Ontario, including immigrants 
after their three months mandatory waiting period, are covered by provincial health insurance and 
are assigned a unique health card number. ICES is authorized to access, link, and analyze health 
administrative data for evidence generation and reforming policies (Ishiguro et al., 2016). The 
specific databases used for this study included the Ontario Cancer Registry (OCR), Ontario Health 
Insurance Plan (OHIP), Discharge Abstract Database (DAD), National Ambulatory Care 
Reporting System (NACRS), and the Registered Person Database (RPDB).  
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     The Ontario Cancer Registry (OCR) contains information about all the patients diagnosed with 
cancer or who died from the disease from 1964 to 2018 (Cancer Care Ontario, 2018). It includes 
the type of cancer, age at diagnosis, sex, and the date of a cancer diagnosis. The data in this registry 
are collected from hospital admission, pathology, physician’s consultation, and death certificates 
(Cancer Care Ontario, n.d.). The morphology and typology codes and stages of cancer were 
obtained from the Ontario Cancer Registry (OCR). The National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) coding system were used to group these codes into types 
such as breast, lung, colorectal, prostate, urinary system, hematological, female reproductive 
system, digestive system except colon and rectum, etc. (National Cancer Institute, 2008).  
     The Ontario Health Insurance Plan (OHIP) claims contain data about the physician’s visits with 
the diagnosis and the procedures performed (Cadarette & Wong, 2015). The Discharge Abstract 
Database (DAD) contains inpatient data from hospitals, including the date of admission, discharge, 
length of stay, diagnosis, and procedures (Cadarette & Wong, 2015). The National Ambulatory 
Care Reporting System (NACRS) encompasses the hospital outpatient data, emergency visits, and 
day surgery procedures (Cadarette & Wong, 2015). The data for the diagnosis of mood disorders, 
arthritis, and other chronic conditions were derived from these three databases. The hospitalization 
data were obtained from the Discharge Abstract Database (DAD) and emergency visits data from 
the National Ambulatory Care Reporting System (NACRS) databases.  
   The Registered Person Database (RPDB), which is comprised of the demographic data of 
persons enrolled in the Ontario Health Insurance Plan, was used to identify the patient’s age, sex, 
income quintile, and place of residence. The unique encrypted patient identifier in the RPDB and 
all health data allow for record linkage across all the databases (Cadarette & Wong, 2015). The 
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place of residence (rural/urban) and the neighborhood income quintiles were derived from the 
RPDB. The rurality index of 0 to 39 is considered as urban and 40 or more as rural. 
    The Ontario Marginalization Index (ON-Marg) is a measure of inequalities between the 
geographical areas based on four dimensions; residential instability, material deprivation, ethnic 
concentration, and dependency (Matheson et al., 2012). For our study purpose, we only considered 
the ethnic concentration quintiles, a higher value indicated a higher proportion of recent 
immigrants (arrived in Canada within the last five years of the census), and self-identified visible 
minorities (Matheson et al., 2012). The detailed description of the databases and related variables 
is summarized in table 1. 
Table 1 
Administrative databases used for the study and the corresponding study variables 
 





Includes data on all person eligible for the 
Ontario Provincial Health care program and 
provides demographic information like age, 
sex, date of birth, death, residence, and 
neighborhood income 






Hospital inpatient data. It includes data on 
hospital admission, discharge, length of 
stay, primary diagnosis, other diagnoses, 
procedures, and interventions 
Arthritis, mood disorders, and 
other comorbidities using the 
ICD codes, date/year of 
diagnosis, hospitalization 
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Physician’s claim database. Includes the 
date of visit, diagnosis, procedures such as 
laboratory tests and vaccination 
Arthritis, mood disorders, and 
other comorbidities using the 







Includes hospital outpatient data, diagnosis, 
day surgeries, and Emergency department 
visits 
Arthritis, mood disorders, and 
other comorbidities using the 
ICD codes, date/year of 
diagnosis, ED visits 
Ontario Cancer 
Registry (OCR) 
Provincial database of all the residents of 
Ontario having a diagnosis of cancer. 
Contains demographic and clinical 
information including the date of diagnosis, 
primary cancer site, cancer stage, and death 
Age, sex, date of birth, death, 
cancer type, date of cancer 
diagnosis 
 
3.6 Ethical Considerations 
    This study was a part of the research project titled “Support complex cancer patients with 
multimorbidity navigate efficiently between health care and cancer care systems.”  Ethics approval 
for the project was obtained from the Lakehead University Research Ethics Board and ICES. As 
the study is based on the administrative databases, informed consent is not required. An ethics 
waiver from the Lakehead University research ethics board was obtained for this thesis. All the 
data are secured at ICES, and the researchers use a secure user interface ICES Data and Analytic 
Services Environment (IDAVE) for accessing and analyzing the data. IDAVE provides a secure 
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virtual interface where all accredited researchers can analyze data with the provided software, and 
the aggregate results are released only after being vetted by ICES, to maintain the privacy and the 
































Chapter 4: Impact of Arthritis on the Development of Mood Disorders in Cancer Patients: 















Objectives: This study aimed to explore the impact of arthritis on the risk of developing mood 
disorders among cancer patients with or without other comorbidities. 
Method: A retrospective population-based cohort study with linked health administrative data was 
conducted. Ontarians diagnosed with cancer between 2003 and 2013 were followed up until March 
2018. Those with pre-existing mood disorders were excluded. The incidence of mood disorders 
was compared between cancer patients with and without arthritis. Survival analysis using Cox 
proportional hazard modeling was performed to assess the adjusted impact of arthritis on the 
development of mood disorders, considering multimorbidity (MMB) and other sociodemographic 
and clinical factors. 
Results: The cohort included 444,552 participants, aged 63 years on average; 51% had arthritis. 
The cumulative incidence of mood disorders was 16.9 (95% CI 16.6-17.3)/1,000 patients, and 
respectively 17.0 (95% CI 16.5-17.6) and 16.8 (95% CI 16.3-17.3) per 1,000 in patients with and 
without arthritis. In the adjusted Cox model, there was no significant difference in the risk of 
developing mood disorders among patients with or without arthritis. The risk of mood disorders 
was higher among males, patients with lung cancer, and patients in stage IV cancer; it increased 
with the level of multimorbidity. The association between arthritis and mood disorders was not 
impacted by the number of other comorbidities. 
Conclusion: The findings showed that arthritis was not associated with increased risk of mood 
disorders, but MMB was a significant risk factor. The study provides evidence for addressing 
multimorbidity among cancer patients to reduce their risk of developing mood disorders as well as 
other psychologic conditions, in order to potentially improve their outcomes. 
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     Mood disorders are a great concern among cancer patients as it impacts their survival, quality 
of life, and care management (Kanani et al., 2016; Pinquart & Duberstein, 2010; Pitman et al., 
2018). In fact, such disorders are quite prevalent in cancer patients and result in reduced survival 
given that depression alters the neuroendocrine and immunological process of the body (Spiegel 
& Giese-Davis, 2003). The prevalence of depressive disorders ranged from 5-60% among cancer 
patients depending on the methods used for diagnosis (Caruso et al., 2017). In a systematic review, 
it was reported that among hospitalized cancer patients, the prevalence of major depressive 
disorder (MDD) was 14-30%, whereas, in cancer outpatients, the MDD prevalence was 5-16% 
(Walker et al., 2014). Cancer recurrence, comorbidities, past psychiatric conditions, advanced 
cancer with metastasis, poor social support, low socio-economic condition, and being single 
represent contributing factors for developing mood disorders (Anuk et al., 2019).  
     In Canada, the life expectancy of cancer survivors has increased from 55 years to 63 years from 
1990 to 2019 (Canadian Cancer Society, 2019). As such, multimorbidity (MMB), i.e. the 
occurrence of two or more chronic conditions is common among cancer patients (Koné Pefoyo et 
al., 2015). More than 75% of cancer patients in Ontario had additional comorbidities and the 
prevalence of MMB can reach up to 92% among the elderly population (Koné Pefoyo et al., 2015; 
Williams et al., 2018). Commonly occurring chronic conditions in cancer patients are 
hypertension, diabetes, musculoskeletal diseases including arthritis, heart failure, anxiety, and 
dementia which may be partly explained by their mutual risk factors with cancer (Gallacher et al., 
2018; Johnson et al., 2016; Luque-Fernandez et al., 2019; Salako et al., 2018). Specifically, 
arthritis and cancer have shared pathological pathways (Yu et al., 2016). For example, the 
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incidence of rheumatic symptoms was significantly higher among breast cancer patients compared 
to those with benign breast disease (Andrykowski et al., 1999).  
     On the other hand, several studies linked arthritis with mood disorders, such as depression 
(Dickens et al., 2002; Husaini & Moore, 1990; Margaretten et al., 2011; Stubbs et al., 2016). 
Patients with arthritis are more likely to have mood disorders, particularly depression (Husaini & 
Moore, 1990) and at least 17% of rheumatoid arthritis patients had a diagnosis of major depressive 
disorder (Alpay, 2000; Sturgeon et al., 2016). In summary, MMB contributes to the complexity of 
cancer patients, especially mood disorders can have an important impact on cancer outcomes, 
while arthritis, one of the most common co-occurring conditions, may contribute to increasing the 
risk of mood disorders in cancer patients. This paper aimed to assess the influence of arthritis on 
the development of mood disorders among cancer patients in Ontario, Canada. We also described 
whether MMB mediates the association between arthritis and mood disorders in cancer patients. 
Methods 
Study Design and Data Sources 
    A retrospective cohort study with health administrative data from the Institute for Clinical 
Evaluative Sciences (ICES) was conducted to assess the effect of arthritis, sociodemographic, and 
other clinical factors on the development of mood disorders in cancer patients. In Ontario, all 
residents are eligible for health coverage and issued a unique health card number, including 
immigrants after their three months mandatory initial waiting period. The specific databases used 
for this study included the Ontario Cancer Registry (OCR), Ontario Health Insurance Plan (OHIP), 
Discharge Abstract Database (DAD), National Ambulatory Care Reporting System (NACRS), and 
the Registered Person Database (RPDB). The detail of the databases is provided in appendix A. 
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The study investigators obtained ethics approval from ICES and Lakehead University Research 
Ethics Board.  
Study Population 
    The study cohort included all adults (aged 18 or older) in Ontario, who were diagnosed with 
cancer between April 1, 2003, and March 31, 2013, and who did not have any pre-existing mood 
disorders (as defined below) to ensure an accurate calculation of the incidence of mood disorders. 
Patients who had died within the first year of cancer diagnosis were excluded to avoid 
underestimation of the incidence of mood disorders, as it may take longer to identify and diagnose 
mental illness after a cancer diagnosis. Moreover, the severity and poor prognosis of certain types 
of cancer might take precedence leading to ignorance of the symptoms of mood disorders including 
depression among these patients masking the association between arthritis and mood disorders. 
The cohort was followed up until March 31, 2018, to identify the occurrence of 18 predefined 
chronic conditions including mood disorders. 
Study Measurements 
    The primary exposure of the study was the presence of arthritis (both osteoarthritis and 
rheumatoid arthritis were considered together), at any time during the study period, but prior to 
mood disorders occurrence, which was a binary variable (yes/no). To identify cases of arthritis, 
ICD-9 codes from OHIP or ICD-10 codes in DAD or NACRS  were used (Appendix B); a patient 
was deemed to have arthritis if he/she had at least two physician’s claims with arthritis within a 
two-year period or one hospital admission or emergency visit with arthritis in one year. When 
rheumatoid arthritis (RA) is identified using one hospitalization ever or two physician’s visit 
within a two year period, Canadian administrative databases have 83% sensitivity and 99% 
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specificity (Widdifield et al., 2014). On the other hand, when osteoarthritis (OA) is diagnosed 
using the definition stated above, administrative databases have low sensitivity but high specificity 
(Shrestha et al., 2016). 
    We were also interested in the impact of MMB on the study outcomes. Besides cancer, arthritis, 
and mood disorders, the chronic conditions included in the study were acute myocardial infarction 
(AMI), asthma, cardiac arrhythmia, chronic obstructive pulmonary disease (COPD), congestive 
heart failure (CHF), chronic coronary syndrome, dementia, diabetes, hypertension (HTN), other 
mental illnesses, osteoporosis, renal failure, and stroke. These conditions were defined using 
validated algorithms where applicable or considering at least two physician's billing claims (OHIP) 
or one hospitalization (DAD or NACRS) for other conditions (Austin et al., 2002; A. S. Gershon 
et al., 2009; Andrea S Gershon et al., 2009; Hux et al., 2002; Jaakkimainen et al., 2016; Schultz et 
al., 2013; Tu et al., 2007). The chronic conditions included in this study were chosen based on 
their population burden and associated cost (Koné Pefoyo et al., 2015; Woodchis et al., 2016). The 
ICD codes for identifying the selected chronic conditions are provided in Appendix B. We counted 
the number of chronic conditions and classified as no conditions, 1, 2, 3, and 4 or more conditions.     
   The outcome was the time to development of mood disorders in cancer patients following a 
cancer diagnosis. Mood disorders were measured using specific ICD-9 and ICD-10 codes in OHIP, 
DAD, and NACRS (Appendix B). The patients were considered to have mood disorders whey they 
had at least two claims with mood disorders in OHIP in the last two years or one registration with 
DAD or NACRS in the previous one year.  A study conducted by Fiest et al. (2014) described that 
if cases of depression were diagnosed using the case definition of one or more hospital admission 
in one year or 2 or more physician’s claims in two years, the sensitivity of DAD and OHIP database 
is 75% and specificity is 93% for diagnosing depression (Fiest et al., 2014). Other covariates 
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included in the study consisted of age, sex, ethnicity, place of residence, income quintile, cancer 
types, and stage. Age, sex, and the morphology and typology codes using The National Cancer 
Institute’s Surveillance, Epidemiology, and End Results (SEER) coding system and stages of 
cancer were derived from the Ontario Cancer Registry (OCR) (National Cancer Institute, 2008). 
Ethnic concentration quintiles were obtained from the Ontario Marginalization Index (ON-Marg) 
and a higher value (Q1 to Q5) indicated a higher proportion of recent immigrants, and self-
identified visible minorities (Matheson et al., 2012). The place of residence (rural/urban) and the 
neighborhood income quintiles were derived from the RPDB. A rurality index of 0 to 39 were 
considered as urban and 40 or more as rural. Neighborhood income quintiles are based on census 
data; quintile 1 (Q1) has the lowest and quintile 5 (Q5) has the highest income (Specifications, 
n.d.). 
Analyses 
         All the statistical analyses were performed using SAS software (SAS Institute, n.d.), on the 
remote secured ICES platform. Descriptive and bivariate analyses were used to describe the study 
population's demographic and clinical characteristics as well as to assess the relationship between 
the patient's sociodemographic characteristics, cancer type, number of other comorbidities, 
arthritis, and the development of mood disorders. The crude incidence of mood disorders was 
calculated and compared between cancer patients with or without pre-existing arthritis. We 
constructed a Kaplan-Meier curve and performed a log-rank test to identify the crude impact of 
arthritis (exposure) on time to the development of mood disorders (outcome) in cancer patients. 
Finally, a Cox proportional hazard model was fitted to study the adjusted effect of arthritis on the 
development of mood disorders. To investigate whether the role of arthritis on the development of 
mood disorders was modified by the number of other comorbid conditions, an interaction term 
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between arthritis and the number of chronic conditions was tested in the model. The model was 
also stratified by cancer type to evaluate whether the impact of arthritis on the development of 
mood disorders varied by cancer types (effect modification). 
Results 
     The study included 444,552 adult patients with cancer living in Ontario, who survived at least 
one year after their cancer diagnosis and did not have any pre-existing mood disorders. The mean 
age of the population was 63.2 years, most had breast, colorectal, or prostate cancer. Around 87% 
of the patients had MMB, and 50.77% had a diagnosis of arthritis (Table 1). The association 
between sociodemographic and clinical characteristics and arthritis are also described in Table 1. 
The patients with arthritis were older, and more likely to have additional conditions, mostly female, 
from a higher sociodemographic background, and had mostly breast or prostate cancer.  
Table 1. 





With arthritis prior to 
mood disorders  
N = 225,697  
(%) 
Without arthritis prior 
to mood disorders  
N = 218,855  
(%) 
P-value 
Arthritis prior to mood 
disorders 
   - 
Yes 50.8 100 -  
Age at cancer diagnosis 
(years) 
   <0.0001 
Mean (SD) 63.2 ± 
14.2 
65.6 ± 12.9 60.7 ± 14.9  
Range (min-max) 18-103 18-103 18-103  
Sex    <0.0001 
Male 50.3 48.3 52.4  
Income Quintile    <0.0001 
Q1 17.7 17.8 17.5  
Q2 19.8 20.0 19.6  
Q3 19.7 19.8 19.7  
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Q4 20.8 20.6 21.1  
Q5 21.9 21.8 22.1  
Ethnic Concentration    0.39 
Q1 21.0 21.0 21.0  
Q2 20.2 20.3 20.2  
Q3 19.4 19.3 19.5  
Q4 19.0 19.0 19.0  
Q5 20.3 20.3 20.3  
Place of Residence    <0.0001 
Rural 13.9 13.5 14.3  
Type of Cancer    <0.0001 
Breast 17.0 18.0 16.1  
Colon and rectum 12.6 12.1 13.1  
Digestive system 
except colon and 
rectum 
4.7 4.3 5.1  
Female genital 6.8 6.7 6.8  
Lung and bronchus 6.4 6.2 6.7  
Prostate 18.5 19.3 17.7  
Others 18.7 17.5 19.9  
Haematological 8.8 9.0 8.6  
Urinary system 6.5 6.9 6.0  
Cancer Stage    <0.0001 
I 16.9 17.8 16.0  
II 21.6 22.2 21.1  
III 10.8 10.0 11.6  
IV 6.7 5.6 7.8  
Unknown 44.0 44.4 43.5  
Number of Other 
Comorbidities 
   <0.0001 
0 13.1 8.4 17.9  
1 23.2 19.7 26.8  
2 22.2 22.4 22.1  
3 16.5 18.6 14.4  
4+ 25.0 30.9 18.8  
Death in the study 
period 
   <0.0001 
Yes 37.8 36.8 38.8  
 
    Table 2 shows the cumulative incidence of mood disorders, overall, and according to the 
patient’s sociodemographic and clinical characteristics. The cumulative incidence of mood 
disorders in the study population was 16.9 (95% CI 16.6-17.3) per 1,000. Among those with 
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arthritis, 17.0 (95% CI 16.5-17.6)  per 1000 and among the patients without arthritis 16.8 (95% CI 
16.3-17.3)  per 1,000 population developed mood disorders. The risk of mood disorders was higher 
with an increasing number of additional comorbidities, among younger patients, females, in lower 
socio-economic conditions, and rural residents. The patients with lung, hematological, and urinary 
system cancer had a higher incidence of mood disorders.  
Table 2. 
Crude incidence of mood disorders in cancer patients overall, by arthritis status and other 
characteristics 
Characteristics N with 
mood 
disorders 
Cumulative incidence of 




All population 7,526 16.9 (16.6-17.3) N/A 
Presence of arthritis prior to 
mood disorders 
   
Yes 3,847 17.0 (16.5-17.6) 0.54 
No 3,679 16.8 (16.3-17.3)   
Age Group    
18-44 962 21.3 (19.9-22.6) <0.0001 
45-64 2,993 16.7 (16.1-17.3) 
>=65 3,571 16.2 (15.7-16.8) 
Sex    
Male 3,381 15.1 (14.6-15.6) <0.0001 
Female 4,145 18.8 (18.2-19.3) 
Income Quintile    
Q1 1,653 21.1 (20.1-22.2) <0.0001 
Q2 1,567 17.9 (17.0-18.7) 
Q3 1,441 16.5 (15.6-17.3) 
Q4 1,388 15.0 (14.3-15.8) 
Q5 1,446 14.9 (14.1-15.6) 
Ethnic Concentration    
Q1 1,562 16.9 (16.1-17.8) 0.50 
Q2 1,491 16.8 (15.9-17.6) 
Q3 1,444 16.9 (16.0-17.8) 
Q4 1,453 17.4 (6.5-18.3) 
Q5 1,455 16.3 (15.5-17.1) 
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Place of Residence    
Rural 1,118 18.1 (17.1-19.2) 0.01 
Urban 6,401 16.7 (16.3-17.1) 
Type of Cancer    
Breast 1,353 17.9 (16.9-18.8) <0.0001 
Colon and rectum 945 16.9 (15.8-18.0) 
Digestive system except colon 
and rectum 
376 18.1 (16.3-19.9) 
Female genital 526 17.5 (16.0-19.0) 
Lung and bronchus 546 19.1 (17.5-20.7) 
Prostate 966 11.7 (11.0-12.5) 
Others 1,401 16.9 (16.0-18.7) 
Haematological 894 22.9 (21.4-24.4) 
Urinary system 519 18.0 (16.5-19.6) 
Cancer Stage    
I 1,180 15.7 (14.8-16.6) <0.0001 
II 1,331 13.8 (13.1-14.6) 
III 765 16.0 (14.8-17.1) 
IV 489 16.5 (15.0-17.9) 
Unknown 3,761 19.2 (18.6-19.9) 
Number of Other Comorbidities    
0 199 3.4 (2.9-3.9) <0.0001 
1 1,205 11.7 (11.0-12.4) 
2 1,449 14.7 (13.9-15.4) 
3 1,382 18.8 (17.8-19.8) 
4+ 3,291 29.6 (28.6-30.6) 
Death during the study period   <0.0001 
Yes 4,095 24.4 (23.6-25.1)  
No 3,431 12.4 (12.0-12.8)  
 
Crude Impact of Arthritis and MMB on the Time to the Development of Mood Disorders 
     The Kaplan Mayer (K-M) curve in figure 1 showed that the probability of developing mood 
disorders was significantly higher (p<0.0001) in cancer patients without arthritis compared to those 
with arthritis. The difference in the impact of arthritis on the development of mood disorders was 
substantial only 2 years after the initial cancer diagnosis (confidence intervals overlapped after 2 
years). However, it should be noted that patients without arthritis were younger and had a higher 
prevalence of stage III or IV cancer (19.4% vs. 15.6%) than patients with arthritis. Both younger 
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age and stage III or IV cancer were associated with increased risk of mood disorders, which might 
explain the higher probability of developing mood disorders in patients without arthritis over time. 
However, the impact of arthritis on the development of mood disorders adjusted for age and stage 
of cancer will be tested in the Cox model.  
    On the other hand, the time to developing mood disorders was significantly shorter among 
patients without any other comorbidities and the time to mood disorders increased with the 
presence of additional comorbidities (results not shown). Perhaps, people with multiple 
comorbidities had misattribution of their depressive symptoms with the symptoms of other chronic 
conditions leading to significantly less likelihood of reporting mood disorders. Arthritis was 
associated with a lower probability of developing mood disorders in patients with cancer over time 
irrespective of the number of other co-occurring chronic conditions (appendix C).  
Fig 1: Time to the development of mood disorders in cancer patients with or without arthritis 
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    A multivariate Cox Proportional Hazard Model was then fitted to examine the adjusted impact 
of arthritis and MMB on the development of mood disorders in cancer patients. The covariates 
included in the multivariate analysis were tested for proportionality by using LLS (log of negative 
log of estimated survivor functions versus the log of time) curve and Schoenfeld residuals test. As 
a result, arthritis, multimorbidity, and age were included in the Cox hazard model as time-varying 
covariates, using interaction with the log of time. All the other covariates were proportional.  
Adjusted Impact of Arthritis on the Development of Mood Disorders, Overall and by 
Cancer Types 
Table 3. 
Adjusted impact of arthritis on the development of mood disorders in cancer patients 
Characteristics Hazard 
Ratio 
95% CI of HR 
Arthritis (ref = no) Yes 1.19 0.92-1.55 
Arthritis*log(time)   0.97 (p=0.09)  
Age  1.49 1.48-1.51 
Age*log (time)  0.94 (p<0.0001)  
Sex (ref = male) Female 0.92 0.87-0.97 
Rural (ref = no) Yes 0.95 0.88-1.02 
Income Quintile (ref 
= Q5)  
Q1 0.98 0.91-1.06 
Q2 0.97 0.90-1.04 
Q3 0.99 0.93-1.07 
Q4 0.98 0.91-1.05 
Ethnic Concentration 
Quintile 
(ref = Q5)  
Q1 1.08 1.00-1.17 
Q2 1.06 0.98-1.14 
Q3 1.06 0.98-1.15 
Q4 1.07 0.99-1.15 
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95% CI of HR 
Cancer Types (ref = 
others) 
Breast 1.14 1.05-1.24 
Colon and rectum 1.11 1.01-1.21 
Digestive system 
except colon and 
rectum 
1.19 1.06-1.34 
Female genital 1.18 1.06-1.32 
Hematological 1.02 0.93-1.11 
Lung and bronchus 1.26 1.14-1.40 
Prostate 1.15 1.04-1.26 
Urinary system 1.09 0.98-1.21 
Presence of other 
comorbid conditions 
(ref = no other 
conditions) 
1 other condition 1.67 1.35-2.08 
2 other conditions 4.46 3.14-6.33 
3 other conditions 10.85 6.63-17.74 





 0.89 (p <0.0001)  
Cancer stage (ref =I) II 1.05 0.97-1.14 
 
III 1.06 0.98-1.18 
IV 1.18 1.08-1.35 
Unknown 1.00 0.94-1.08 
Death during the 
study period (ref = 
no) 
Yes 1.08 1.02-1.15 
 
     After adjusting for age, sex, residence, income, ethnicity, cancer types, stage, and the number 
of other comorbid conditions, arthritis did not remain significantly associated with an increased 
risk of mood disorders in cancer patients. The association did not vary according to time either. 
The adjusted impact of arthritis also did not vary according to MMB level (interaction not 
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significant, results not shown). MMB was associated with the risk of mood disorders, and its 
impact decreased with time. Other significant risk factors for developing mood disorders were 
increasing age, male sex, certain cancer types, stage IV cancer, and death within the study period. 
Cancer patients who died at any point during the study period had a higher probability of 
developing mood disorders than those who were still alive.  
    We looked at the impact of different types of arthritis (osteoarthritis and rheumatoid arthritis) 
on the development of mood disorders. There was no impact of osteoarthritis and rheumatoid 
arthritis on the risk of mood disorders at baseline and over time. Then we performed stratified 
analyses by cancer types to determine whether the impact of arthritis and MMB on the 
development of mood disorders varied by the clinical aspects of cancer. Cancer types are clinically 
different and may impact differently care management or patient outcomes including the risk of 
mood disorders, hence, the relevance to stratify. Arthritis was associated with the highest risk of 
mood disorders at baseline among patients with lung (HR 5.73; CI 1.85-17.75), prostate (HR 4.12; 
CI 1.49-11.33), and urinary system (HR 6.16; CI 1.95-19.44) cancers. The risk of mood disorders 
decreased significantly with time among all the three above-mentioned cancer groups. On the other 
hand, the baseline risk of mood disorders was lowest among breast cancer patients with arthritis 
(HR 0.45; CI 0.21-0.99) which did not vary over time (Table 4). Nevertheless, among the patients 
with colon and other digestive systems, female genital or hematological cancer, arthritis was not 
linked significantly with the development of mood disorders.  
Table 4. 
Adjusted Impact of arthritis on the development of mood disorders stratified by cancer types 
Cancer Type Description Hazard ratio 95% Confidence interval 
Breast Arthritis Yes vs No 0.45 0.21 0.99 
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Arthritis* log (time) 1.10 (p=0.11)   
Colon and rectum Arthritis Yes vs No 0.50 0.24 1.05 
Arthritis* log (time) 1.10 (p=0.08)   
Digestive system except 
colon and rectum 
Arthritis Yes vs No 0.92 0.24 3.51 
Arthritis* log (time) 0.99 (p=0.94)   
Female genital Arthritis Yes vs No 1.01 0.28 3.68 
Arthritis* log (time) 1.00 (p=0.99)   
Hematological Arthritis Yes vs No 0.98 0.45 2.14 
Arthritis* log (time) 0.99 (p=0.79)   
Lung and bronchus Arthritis Yes vs No 5.73 1.85 17.75 
Arthritis* log (time) 0.77 (p=0.003)   
Prostate Arthritis Yes vs No 4.12 1.49 11.33 
Arthritis* log (time) 0.81 (p=0.003)   
Urinary system Arthritis Yes vs No 6.16 1.95 19.44 
Arthritis* log (time) 0.77 (p=0.003)   
 
*Adjusted for age, sex, residence, income, ethnic concentration, cancer stage, MMB level, and 
death during the study period. 
Sensitivity Analysis 
     A sensitivity analysis was performed among patients who survived less than a year after the 
cancer diagnosis (N = 144,207) to explore whether arthritis and MMB had similar effects on the 
development of mood disorders in this group of patients. These patients were older (mean age 72.8 
years), more likely to be male, be diagnosed with lung cancer, and only 40% had arthritis prior to 
mood disorders (Appendix E). The cumulative incidence of mood disorders was lower, 7.1 per 
1,000 population, and slightly but not statistically different between patients with arthritis (7.5 per 
1,000), and those without arthritis (6.8 per 1,000). In the multivariate Cox model, arthritis and 
MMB did not have a significant association with mood disorders (Appendix F).          
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    This study examined the impact of arthritis on the development of mood disorders in cancer 
patients considering the role of other comorbid conditions. The findings showed that arthritis was 
not associated with the risk and time to development of mood disorders.  
    We found an overall incidence of mood disorders of 16.9 per 1000 among cancer patients, which 
is consistent with previous population-based studies (Hung et al., 2013; Zhu et al., 2017). The 
study by Zhu et al. (2017) was among the Swedish cancer patients who are comparable to the 
Canadian population according to the sociodemographic characteristics. Zhu et al. (2017) found 
that the incidence of mood disorders including depression was 13.9 per 1,000 population (J. Zhu 
et al., 2017). However, they only considered major depressive disorders which might explain the 
relatively lower incidence found in their study. 
  Our study showed that arthritis was not associated with an increased risk of mood disorders in 
cancer patients. Several studies have focused on the association between arthritis and mood 
disorders in the general population, but no study have addressed this issue among cancer patients 
specifically. As opposed to our findings, all these studies showed that arthritis was associated with 
increased risk of mood disorders (He et al., 2008; Hsu et al., 2014; Husaini & Moore, 1990; Jeong 
et al., 2017; Stubbs et al., 2016). He et al. (2008) found 1.9 times higher odds of mood disorders 
in patients with arthritis compared to those without arthritis (He et al., 2008). Stubbs and colleagues 
(2016) found a 17% higher risk of depression among osteoarthritis patients (Stubbs et al., 2016). 
Both cancer and arthritis are characterized by pain which is a significant predictor of depression 
(Alemayehu et al., 2018). So, we expected a higher association between arthritis and mood 
disorders in cancer patients. However, this hypothesis was not confirmed. The K-M curve showed 
that arthritis was associated with decreased risk of mood disorders up to two years after cancer 
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diagnosis and the impact of arthritis on the risk of mood disorders later subsided. In the Cox model, 
after adjusting for covariates, arthritis showed no association with mood disorders in cancer 
patients. Perhaps, the uncontrolled pain associated with arthritis could obfuscate mood disorder 
symptoms leading to ignoring and under-reporting the psychological condition in cancer patients 
with arthritis. Besides, the severity of certain cancers could predispose the patients to develop 
mood disorders masking the impact of arthritis. 
     While the specific condition arthritis was not a risk factor, our study found the number of other 
comorbidities was associated with an increased risk of developing mood disorders both among the 
cancer patients with and without arthritis. Patients with four or more additional conditions had 
around 21 times higher risk of mood disorders at baseline compared to those without other chronic 
conditions but the risk decreased over time. This finding is consistent with the previous literature 
(Rice et al., 2018; Zoorob et al., 2019). However, the above-mentioned studies did not consider 
the impact of MMB over time and our study showed that the risk of mood disorders associated 
with MMB decreased over time. Complex cancer patients suffering from MMB for a longer period 
could ignore psychological conditions due to the severity of other conditions which might lead to 
the diminished impact of MMB on mood disorders later after their cancer diagnosis.  
    Other risk factors included were increasing age and male sex. The increased risk of mood 
disorders related to male sex found in our study is contrary to previous studies where female sex 
had been described as a risk factor for developing mood disorders (Walker et al., 2014). In our 
study, the crude incidence of mood disorders was higher among the females but after adjusting for 
the covariates, male sex became a significant risk factor for mood disorders. Male patients were 
older, had a higher number of comorbidities. Elderly patients were more likely to develop late-
stage cancer and had MMB. Both MMB and stage III and IV cancers are proven risk factors for 
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mood disorders (Zoorob et al., 2019; Walker et al., 2014), and this might explain the increased risk 
of mood disorders associated with age and among the males when adjusted for the confounders 
like cancer stage and number of other chronic conditions.  
     When looking at the association between arthritis and mood disorders within cancer types we 
found that the impact of arthritis on the risk of mood disorders was highest at the baseline among 
lung cancer patients. In these patients, with the advancement of cancer, the severity of the disease 
and related complications might be responsible for causing depression. As a result, the impact of 
arthritis on the development of mood disorders was diluted over time in lung cancer patients. On 
the contrary, breast cancer patients had a lower baseline risk of mood disorders when they had 
arthritis, but the impact of arthritis increased over time. Generally, breast cancer patients had better 
survival, and many of them suffered from arthritis for a longer period. There are common drugs 
used to treat arthritis and cancer, for example, steroid has been linked to increased risk of 
depression (Caruso et al., 2017). As a result, the impact of arthritis on the risk of mood disorders 
could increase from the baseline risk later after a cancer diagnosis.  
Strengths and Limitations 
    The cases of mood disorders were diagnosed using ICD-10 codes in hospitalization or 
physician’s claim data and ICD-9 code in OHIP, DAD, and NACRS. The OHIP database contains 
ICD-9 codes 296 (Major Depression/ Bipolar disorder), 300 (Anxiety neurosis, hysteria, 
neurasthenia, obsessive-compulsive neurosis, reactive depression), and 311 (Depressive Disorder 
NOS) for classifying mood disorders. In DAD and NACRS, mood disorders are classified using 
ICD-10 codes F30-34, F38-39 (Grigoriadis et al., 2017). We included ICD 10 codes F30-34, F38-
39 in DAD or NACRS but ICD-9 code 296 only from OHIP and did not consider 300 and 311 to 
identify cases of mood disorders. However, linking the databases to include the patients of mood 
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disorders from both hospitalizations and physician claim data enabled us to get a precise estimate 
of the incidence of mood disorders. Moreover, ICD 9 codes 300 and 311 is not specific for 
depression; hence they were not considered to diagnose the cases of mood disorders.        
     The study was conducted with the administrative health databases and included only those 
cancer patients having contact with the health care system. However, all the adult cancer patients 
diagnosed between 2003-2013 were considered in the study and despite the limitation of including 
only those having contact with the health care system, the overall coverage was good. Cancer 
patients who died within their first year of diagnosis were not considered in the study leading to 
potential selection bias. A sensitivity analysis was conducted to examine the role of arthritis and 
MMB in developing mood disorders among cancer patients who survived less than a year. The 
findings showed that arthritis had similarly no effect on the development of mood disorders among 
these cancer patients. In contrast to the patients surviving greater than a year, MMB was also not 
linked to the development of mood disorders in cancer patients surviving less than a year. Hence, 
it is more relevant to address MMB including arthritis in cancer patients who survived longer to 
improve their psychological outcomes.  
     There might be a misclassification bias while reporting arthritis and mood disorders by either 
patients or physicians. Administrative data, for example, DAD has 85% accuracy for diagnostic 
code (Juurlink et al., 2006). We probably underestimated the incidence of mood disorders due to 
the misclassification introduced by using administrative data. Moreover, the definition used in this 
study to identify the cases of osteoarthritis from administrative databases showed lower 
sensisitivity while having higher specificity (Shrestha et al., 2016). So, there might be under 
estimation of the prevalence of arthritis diluting its effect on the development of mood disorders 
in cancer patients. Furthermore, many comorbid conditions occurred after the diagnosis of mood 
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disorders. So, there was chance of an error in counting the number of comorbid conditions, causing 
misclassification. We considered 16 selected chronic conditions due to their population prevalence 
and associated costs. There are other severe chronic conditions, for example, congenital anomalies, 
thyroid problems, glaucoma, or chronic skin diseases that may be relevant but not included in the 
study. Besides, while observing the impact of MMB, we only counted the number of chronic 
conditions without contemplating their severity and time of occurrence.  
      Despite the limitations, the study had many strengths in terms of data used, study design, and 
analytical approach. It was a population-based retrospective cohort study including all adults in 
Ontario diagnosed with cancer between 2003 and 2013 and without preexisting mood disorders. 
The sample size was large and the follow-up period was between 5 to 15 years, allowing us to 
achieve a long-term estimate of the incidence of mood disorders in cancer patients at the population 
level. We detected mood disorders, arthritis, and other chronic conditions from various Canadian 
administrative databases. Moreover, ICES databases are evidence-based and extensively used in 
the similar literature on MMB (Griffith et al., 2019; Gruneir et al., 2016; Koné Pefoyo et al., 2015; 
Moin et al., 2018; Mondor et al., 2017, 2018; Ryan et al., 2018). 
Conclusion 
   The study revealed that arthritis did not increase the risk of mood disorders, instead, MMB is 
associated with the occurrence of mood disorders in cancer patients. The association between 
arthritis and mood disorders was similar over the study period indicating that arthritis did not 
increase the risk of mood disorders at any point in time in cancer patients. On the other hand, the 
risk of mood disorders increased with the number of chronic conditions at baseline but the impact 
of MMB decreased with the advancement of cancer. The study also provided insight into other 
sociodemographic and clinical factors increasing the risk of depression in cancer patients.  
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    Mood disorders impact cancer outcomes including survival, quality of life, cancer management, 
and health care utilization (Iglay et al., 2017; Mehta & Roth, 2015; Villarreal-Garza et al., 2019). 
Cancer patients with psychological conditions have lower survival and the management of cancer 
becomes complicated in the presence of mood disorders. We found that mood disorders were more 
prevalent among male cancer patients, patients with lung and digestive system cancer in advanced-
stage cancer. This study provides evidence for addressing multimorbidity to decrease the incidence 
of comorbid psychiatric disorders in cancer patients. To ensure proper care management in cancer 
patients, the disease clusters highly responsible for developing mood disorders should be identified 
and treated early. Future research can be done to detect the disease clusters within each MMB level 
associated with the highest risk of mood disorders. Identifying cancer patients most susceptible to 
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Appendix A: Administrative Databases Used in the Study and Corresponding Variables 





Includes data on all person eligible for the 
Ontario Provincial Health care program 
and provides demographic information like 
age, sex, date of birth, death, residence, 
and neighborhood income 





Hospital inpatient data. It includes data on 
hospital admission, discharge, length of 
stay, primary diagnosis, other diagnoses, 
procedures, and interventions 
Arthritis, mood disorders, and 
other comorbidities using the 





Physician’s claim database. Includes the 
date of visit, diagnosis, procedures such as 
laboratory tests and vaccination 
Arthritis, mood disorders, and 
other comorbidities using the 







Includes hospital outpatient data, 
diagnosis, day surgeries, and Emergency 
department visits 
Arthritis, mood disorders, and 
other comorbidities using the 
ICD codes, date/year of 
diagnosis 
76 






Provincial database of all the residents of 
Ontario having a diagnosis of cancer. 
Contains demographic and clinical 
information including the date of 
diagnosis, primary cancer site, cancer 
stage, and death 
Age, sex, date of birth, death, 






It is a measure of inequalities between the 
geographical areas based on four 
dimensions; residential instability, material 
deprivation, ethnic concentration, and 
dependency 














Appendix B: ICD codes for chronic conditions 
Condition ICD 9 / OHIP ICD 10 
AMI 410 I21, I22 
Arthritis - Osteoarthritis 715 M15-M19 
Arthritis - Other Arthritis 
(Synovitis, Fibrositis, 
Connective tissue disorders, 
Ankylosing spondylitis, Gout 
Traumatic arthritis, pyogenic 
arthritis, Joint derangement, 
Dupuytren’s contracture, 
Other MSK disorders) 
727, 729, 710, 720, 274, 716, 
711, 718, 728, 739 
M00-M03, M07, M10, M11-
M14, M20-M25, M30-M36, 
M65-M79 




Asthma 493 J45 
Cancer 140-239 C00-C26, C30-C44, C45-C97 
Cardiac Arrythmia 427.3 (DAD) / 427 (OHIP) I48.0, I48.1 
CHF 428 I500, I501, I509 
COPD 491, 492, 496 J41, J43, J44 
Dementia 
290, 331, 797 (OHIP) / 290.0, 
290.1, 290.3, 290.4, 290.8, 
290.9, 294.1, 294.8, 294.9, 
F000, F001, F002, F009, 
F010, F011, F012, F013, 
F018, F019, F020, F021, 
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331.0, 331.1, 331.2, 797 
(DAD) 
F022, F023, F024, F028, F03, 
F051, F065, F066, F068, 
F069, F09, G300, G301, 
G308, G309, G310, G311, 
R54 
Mood Disorders 296 F30-F34, F38, F39 
Diabetes 250 E08 - E13 
Hypertension 401, 402, 403, 404, 405 I10, I11, I12, I13, I15 
Osteoporosis 733 M81 M82 
Renal failure 403, 404, 584, 585, 586, v451 
N17, N18, N19, T82.4, 
Z49.2, Z99.2 
Stroke 430, 431, 432, 434, 436 I60-I64 
Coronary syndrome 
(excluding MI) 411-414 I20, I22-I25 
Other mental disorders 
(substance use disorder, 
psychotic disorder, anxiety, 
stress reaction-specifically 
PTSD, personality disorder) 
291, 292, 303, 304, 305, 295, 
298, 297, 300, 308, 301 
F10-F19, F55, F20-F29, F40-









Appendix C: K-M Curve Representing the Impact of Arthritis on the Time to the 








Appendix D: Adjusted Impact of Arthritis on the Development of Mood Disorders at 
Different MMB Level 
Description Point Estimate 95% Wald Confidence Limits 
No other comorbidities (arthritis yes vs no) 0.92 0.59 1.43 
1 other condition (arthritis yes vs no) 1.07 0.77 1.49 
2 other conditions (arthritis yes vs no) 1.05 0.77 1.43 
3 other conditions (arthritis yes vs no) 1.15 0.85 1.55 
4 or more other conditions (arthritis yes vs no) 1.14 0.87 1.50 

















Appendix E: Characteristics of Cancer Patients by the length of survival (Less than a Year 
vs More than a Year) 
Characteristics All the Cancer 
patients  




than a year 
N=444,552 
  (%) 
Patients 
surviving less 
than a year 
N=144,207 
(%) 
Development of mood 
disorders 
   
Yes 1.4 1.7 0.7 
Arthritis prior to mood 
disorders 
   
Yes 48.1 50.8 39.7 
Age at cancer diagnosis (years)    
Mean (SD) 65.6 ± 14.4 63.2 ± 14.2 72.8 ± 12.6 
Range (min-max) 18-103 18-103 18-103 
Sex    
Male 51.2 50.3 54.1 
Income Quintile    
Q1 18.9 17.7 22.7 
Q2 20.3 19.8 21.8 
Q3 19.7 19.7 19.6 
Q4 20.3 20.8 18.6 
Q5 20.8 21.9 17.1 
Ethnic Concentration    
Q1 21.7 21.0 23.7 
Q2 20.6 20.2 21.9 
Q3 19.4 19.4 19.1 
Q4 18.7 19.0 17.9 
Q5 19.6 20.3 17.3 
Place of Residence    
Rural 14.3 13.9 15.4 
Type of Cancer    
Breast 13.5 17.0 2.8 
Colon and rectum 12.0 12.6 10.0 
Digestive system except colon 
and rectum 
8.2 4.7 19.2 
Female genital 6.0 6.8 3.7 
Lung and bronchus 12.5 6.4 31.2 
Prostate 14.6 18.5 2.7 
Others 18.0 18.7 15.9 
Haematological 9.0 8.8 9.5 
Urinary system 6.1 6.5 5.1 
Cancer Stage    
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I 13.3 16.9 2.1 
II 17.2 21.6 3.6 
III 10.2 10.8 8.3 
IV 11.6 6.7 26.7 
Unknown 47.7 44.0 59.3 
Number of Other 
Comorbidities 
   
0 12.7 13.1 11.6 
1 22.3 23.2 19.7 
2 22.1 22.2 21.7 
3 16.9 16.5 18.0 



















Appendix F: Adjusted Impact of Arthritis on the Development of Mood Disorders among 
Cancer Patients Surviving Less than a Year 
Characteristics p-value Hazard 
Ratio 
95% CI of 
HR 
Arthritis (ref = no) Yes 0.52 0.96 0.84-1.09 
Age  0.04 1.006 1.00-1.01 
Sex (ref = male) Female 0.05 1.14 0.99-1.30 
Rural (ref = no) Yes 0.84 1.14 0.99-1.30 
Income Quintile (ref 
= Q5)  
Q1 0.84 1.02 0.83-1.25 
Q2 0.94 0.99 0.81-1.21 
Q3 0.43 0.92 0.75-1.13 
Q4 0.84 0.98 0.79-1.21 
Ethnic Concentration 
Quintile (ref = Q5)  
Q1 0.85 1.02 0.82-1.27 
Q2 0.86 1.02 0.83-1.25 
Q3 0.22 0.88 0.71-1.08 
Q4 0.23 0.88 0.72-1.08 
Cancer Types (ref = 
others) 
Breast 0.78 0.94 0.63-1.41 
Colon and 
rectum 
0.48 0.91 0.71-1.17 
Digestive system 
except colon and 
rectum 
0.72 0.96 0.78-1.19 
Female genital 0.84 1.04 0.71-1.51 
Hematological 0.65 0.95 0.74-1.20 
Lung and 
bronchus 
0.58 0.94 0.76-1.16 
Prostate 0.02 0.63 0.43-0.94 
Urinary system 0.09 0.79 0.60-1.03 
Presence of other 
comorbid conditions 
1 other condition 0.05 1.32 1.00-1.73 
2 other 
conditions 
0.20 1.19 0.90-1.56 
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Characteristics p-value Hazard 
Ratio 
95% CI of 
HR 




0.07 1.29 0.97-1.71 
4 or more other 
conditions 
0.33 1.14 0.87-1.50 
Cancer stage (ref = I) II 0.46 1.17 0.77-1.79 
III 0.47 1.15 0.78-1.70 
IV 0.07 1.39 0.97-2.00 




















































Background: Mood disorders and arthritis are common in cancer patients and impact their 
outcomes. Because cancer patients often have multiple conditions, this may exacerbate the effect 
of mood disorders and arthritis on their use of health services. This study will evaluate the impact 
of mood disorders and arthritis on health care utilization (HCU) among cancer patients and how it 
may differ with additional comorbidities. 
Method: A retrospective cohort study using health administrative data was conducted. The study 
population included those who were diagnosed with cancer between April 1, 2003, and March 31, 
2013, and survived at least a year thereafter. They were followed up till 31st March 2018 to identify 
the occurrence of arthritis and mood disorders as well as to measure their health care utilization 
(HCU) following a cancer diagnosis. A negative binomial model was fitted to assess the adjusted 
impact of mood disorders, arthritis, and comorbidities on the health care utilization of cancer 
patients in terms of hospitalizations and emergency visits. 
Results: The study population included 453,012 participants. Among the cancer patients, 51.03% 
had a diagnosis of arthritis and 3.52% had mood disorders. Compared to patients without mood 
disorders (0.57 ± 0.92), those with mood disorders before (0.73± 1.06 ) and after (1.09 ± 1.33)  
cancer had on average a higher number of hospitalizations per person-year. The average ED visits 
per person-year were also higher in patients with mood disorders before (1.03 ± 1.68 ) and after 
(1.20 ± 2.10 ) cancer compared to those without any mood disorders (0.66 ± 1.25). Arthritis was 
associated with increased ED visits and hospitalizations if diagnosed before cancer but decreased 
hospitalizations and ED visits if diagnosed after cancer. In the multivariate regression model, the 
combined presence of arthritis and mood disorders before and after cancer was associated with a 
25% (95% CI = 20-29%) and 28% (95% CI = 20-37%) higher risk of hospitalization, respectively. 
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Furthermore, the co-occurrence of arthritis and mood disorders had been linked to 75% (95% CI 
= 69-81%) and 60% (95% CI = 50-69%) increased risk of ED visits when both the conditions were 
diagnosed before and after cancer, respectively. The presence of other comorbidities increased 
HCU in cancer patients.  
Significance and Policy Implication: The findings confirm that mood disorders and arthritis are 
important predictors of HCU. Addressing the health care needs of patients with multimorbidity, 
especially mood disorders, and identifying other co-occurring conditions responsible for higher 
utilization of health services will ensure optimum patient care and decrease the burden on the 


















       Cancer patients represent the highest users of the health care system. Cancer patients with 
multimorbidity (MMB) (i.e. complex cancer patients) have, on average, 6.8 primary care visits, 
and 9.7 specialists’ visits per month (ICES, 2014). Several factors, such as sociocultural, 
sociodemographic, social-psychological, organizational, and social systems have been shown to 
contribute to health care utilization (HCU) (Anderson, 1973). For example, Johansson and 
colleagues (2004) found that cancer type, stage, age, comorbidities, functional status, pain, lower 
socioeconomic condition, and survival were all related to HCU among cancer patients (Johansson 
et al., 2004)  
      Cancer patients often have co-occurring chronic conditions, and arthritis and mood disorders 
are among the most common comorbidities in cancer patients (Hartung et al., 2017a; Koné Pefoyo 
et al., 2015; Ng et al., 2018). Both arthritis and mood disorders had been individually linked to 
increased utilization of the health care system (Aubert et al., 2019; Guo et al., 2008; Robinson et 
al., 2016; Wright et al., 2010). Mood disorders including major depressive disorder (MDD)  were 
responsible for a higher number of hospital admissions, health care professional visits, and longer 
hospital stays (Patel et al., 2015; Patten & Beck, 2004). Similarly, multimorbidity (MMB) 
increases HCU in patients with depression, and in the opposite direction, depression increases the 
complexity of multimorbid disease management (Bock et al., 2014; Robinson et al., 2016).  
      Arthritis is also associated with increased HCU both among patients with or without cancer 
(Wright et al., 2010; Jacobi et al., 2001). Patients with osteoarthritis have more annual emergency 
visits, hospitalizations, and physician visits compared to those without osteoarthritis, and their 
HCU is greater with the presence of comorbidities like cardiovascular disease, diabetes, 
psychiatric disorder, and cancer (Wright et al., 2010). In patients with rheumatoid arthritis, 97% 
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had at least one specialist visit, and their use of health services increased with the presence of two 
or more chronic conditions including cardiovascular, respiratory diseases, cancer, and depression 
(Jacobi et al., 2001).  
    Research evidence shows that cancer, arthritis, and mood disorders significantly increase HCU. 
However, their combined effect is unknown. The objective of this study is to reveal the combined 
impact of arthritis and mood disorders on the HCU of cancer patients considering the presence of 
other comorbid conditions.  
Methods 
Study Design and Study Population 
     A retrospective cohort study with health administrative data was conducted to examine the 
impact of arthritis and mood disorders on the HCU of cancer patients in Ontario, Canada. The 
study included all adult patients (18 years or more) with a valid health card, diagnosed with cancer 
in Ontario between April 1, 2003, and March 31, 2013, and who survived at least one year after 
their initial cancer diagnosis. The patients who survived less than a year after their cancer diagnosis 
were excluded to minimize reverse causality because a higher encounter with the health care 
system due to their disease severity might be related to the development of depression or arthritis 
among them. We assessed the occurrence of arthritis, mood disorders from 2003 and the HCU 
following cancer diagnosis in terms of hospitalizations and ED visits until March 2018 or death.  
Data Sources 
     This study was based on provincial administrative databases in Ontario housed at the Institute 
for Clinical Evaluative Sciences (ICES) that were linked to define the study population and 
outcome of interest. ICES is a research organization and the databases contain information on 
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health services utilization, disease registries, and basic population characteristics. All the Ontario 
residents including immigrants are covered by provincial health insurance and are assigned a 
unique health card number. ICES members access, link, and analyze health administrative data 
using this unique identifier (Ishiguro et al., 2016). The specific databases used for this study 
include the Ontario Cancer Registry (OCR), Ontario Health Insurance Plan (OHIP), Discharge 
Abstract Database (DAD), National Ambulatory Care Reporting System (NACRS), and the 
Registered Person Database (RPDB). The details of the databases are described in Appendix A. 
The ethics approval for this study was obtained from ICES and Lakehead University Research 
Ethics Board. 
Study Measures 
     The primary exposure was the presence of mood disorders (yes/no) and arthritis (yes/no). Mood 
disorders and arthritis (both osteoarthritis and rheumatoid arthritis) were identified using specific 
ICD-10 codes in DAD as well as ICD-9 codes in OHIP, DAD, and NACRS (Appendix B). Patients 
who have at least two claims with mood disorders or arthritis in OHIP in any consecutive two 
years or one registration in DAD or NACRS within a year were considered as having arthritis or 
mood disorders. There is evidence that if cases of depression were diagnosed using the case 
definition used in this study, the sensitivity of DAD and OHIP database is 75% and specificity is 
93% for diagnosing depression (Fiest et al., 2014). For identifying patients with arthritis, the 
administrative databases also had good validity (Rahman et al., 2016; Widdifield et al., 2014). 
Arthritis and mood disorders were measured throughout the study period (2003-18) and may have 
been present at the time of cancer diagnosis. The exposure was defined as mood disorders only 
before cancer, mood disorders only after cancer, arthritis only before cancer, arthritis only after 
cancer, both the conditions before cancer, both conditions after cancer, mood disorders 
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before/arthritis after cancer, and arthritis before/mood disorders after cancer.  Besides cancer, 
arthritis, and mood disorders, other chronic conditions included in the study were acute myocardial 
infarction (AMI), asthma, cardiac arrhythmia, chronic obstructive pulmonary disease (COPD), 
congestive heart failure (CHF), chronic coronary syndrome, dementia, diabetes, hypertension 
(HTN), other mental illnesses, osteoporosis, renal failure, and stroke as used in previous research 
on MMB (Koné Pefoyo et al., 2015). These conditions were categorized as no additional 
conditions, 1, 2, 3, and 4 or more additional conditions.  
     HCU between April 1, 2003, and March 31, 2018, represented the outcome of interest and 
included the cumulative number of hospital admissions and ED visits since cancer diagnosis. 
Patients were diagnosed at different times between 2003 and 2013 and may have died during 
follow-up; as such, we calculated the average number of hospitalizations and ED visits accounting 
for person-years (hospitalizations and ED visits per person-year). The other covariates included in 
the study were age, sex, ethnicity, place of residence, income quintile, cancer types, and stage 
which were selected as these factors may impact HCU in cancer patients (Hartung et al., 2017; 
Mausbach & Irwin, 2017; Nikbakhsh et al., 2014; Pitman et al., 2018; Yadav et al., 2019). 
Information on age and sex was derived from the Ontario Cancer Registry (OCR). Ethnic 
concentration quintiles were obtained from the Ontario Marginalization Index (ON-Marg) data 
where Q1 demonstrated the lowest ethnically concentrated and Q5 is the highest ethnically 
concentrated area (Matheson et al., 2012). The place of residence (rural/urban) and the 
neighborhood income quintiles were derived from RPDB. Neighborhood income quintiles are 
based on census data; quintile 1 (Q1) has the lowest income whereas quintile 5 (Q5) has the highest 
(Specifications, n.d.).  Cancer sites and stages were obtained from the Ontario Cancer Registry 
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(OCR) and types were grouped using the National Cancer Institute’s Surveillance, Epidemiology, 
and End Results (SEER) coding system (National Cancer Institute, 2008). 
Analysis  
    All the statistical analyses were performed using SAS software (SAS Institute, n.d.). The 
relationships between arthritis, mood disorders, multimorbidity, and hospitalizations and ED visits 
per person-year were assessed with t-test and ANOVA. Considering that the dependent variables 
(number of hospitalizations and ED visits) were count data, and as the mean and variance were 
unequal, a negative binomial model was fitted to assess the adjusted impact of mood disorders and 
arthritis on the HCU rate among cancer patients. The model was adjusted for sociodemographic 
characteristics, level of multimorbidity, and cancer type and stages. The model was also tested 
including an interaction term between arthritis/mood disorders and the level of multimorbidity to 
identify significant interaction. The association between arthritis, mood disorders, and HCU was 
then analyzed within levels of multimorbidity (MMB) to test if MMB has a modifying effect 
(effect modification). 
Results 
     The sample was comprised of 453,012 adult patients with cancer who were diagnosed between 
2003-13 and survived one year or more after their cancer diagnosis. The average age of the study 
population was 63 years. In the study population, 3.52% had a diagnosis of mood disorders and 
51.03% had arthritis. The proportion of cancer patients diagnosed with mood disorders before and 
after cancer was almost similar, whereas 71.8% of the cancer patients with arthritis received the 
diagnosis of arthritis before cancer. Among the patients who developed mood disorders after their 
cancer diagnosis, the mean time to mood disorders was 3.23 years with a median value of 2.41 
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years. The mean duration of follow up for these patients was 10.39 years and the mean time to 
death for those who died was 5.26 years (Appendix C) 
      On the other hand, in the patients who developed arthritis after cancer, the mean duration until 
the development of arthritis was 3.43 years. The average follow-up time for these patients was 
10.83 years and the mean time to death was 6.69 years (Appendix C). Though mood disorders and 
arthritis after cancer diagnosis was considered as exposure irrespective of their time of occurrence, 
the mean time to diagnosis provides an idea about their time of occurrence and insight about 
whether they contributed to the utilization of health services. As the mean time to the development 
of arthritis and mood disorders were much lower than the mean follow-up time or time to death, it 
is expected that these conditions had probably contributed towards their health care utilizations. 
Moreover, we counted hospitalizations and ED visits after cancer diagnosis till 2018 or death. 
Then we calculated average annual hospitalizations and ED visits per person-year. So, if arthritis 
or mood disorders were diagnosed after initial contact with the health care system, these conditions 
would have impact on the subsequent use of health services by cancer patients. 
     Most of the patients with arthritis and mood disorders were older, predominantly female, more 
likely to have breast and prostate cancer, and had a higher number of other co-occurring conditions 
compared to those without arthritis and mood disorders (Table 1).  
Table 1. 



















































































Age Group           
18-44 10.2 14.5 15.3 17.7 4.5 9.8 6.0 16.1 13.3 6.4 
45-64 40.5 42.5 49.5 40.6 36.0 44.8 48.1 42.9 56.9 37.6 
>65 49.3 43.1 35.3 41.7 59.5 45.5 45.8 41.0 29.7 56.0 
Sex           
Male  50.1 52.5 43.8 48.9 47.7 50.3 36.4 41.4 34.7 42.4 
Income 
Quintile 
          
Q1 17.8 17.4 25.0 22.8 18.1 16.8 25.4 22.6 24.1 21.1 
Q2 19.8 19.6 22.0 21.2 20.1 19.4 20.9 20.6 19.9 20.8 
Q3 19.7 19.7 18.2 18.8 19.9 19.6 18.8 19.3 18.3 19.6 
Q4 20.8 21.1 17.3 18.2 20.5 21.0 17.4 18.6 18.5 18.8 




          
Q1 21.0 21.0 20.0 21.6 21.1 20.7 18.4 19.8 18.5 21.1 
Q2 20.2 20.2 19.0 19.9 20.5 19.7 20.0 20.6 17.3 20.1 
Q3 19.4 19.5 19.9 19.6 19.3 19.4 19.6 18.6 21.4 19.8 
Q4 19.0 18.9 21.3 19.3 18.9 19.2 20.9 19.8 23.1 19.8 
Q5 20.3 20.3 19.7 19.5 20.1 21.0 21.1 21.2 19.6 19.1 
Residence           
Rural  13.9 14.3 12.3 15.5 13.6 13.2 12.6 14.1 12.1 14.5 
Type of 
Cancer 
          
Breast 17.1 16.0 18.2 15.7 17.5 19.3 20.3 21.7 26.8 18.8 
Colon and 
rectum 






4.7 5.1 5.0 5.6 4.7 2.9 5.4 4.4 3.7 4.6 
Female 
genital 
6.8 6.8 8.1 7.4 6.6 7.2 7.4 7.4 8.2 6.4 
Lung and 
bronchus 
6.5 6.7 9.0 7.6 7.1 3.6 10.2 4.8 4.3 7.9 
Prostate 18.4 17.8 12.9 12.3 18.3 22.6 11.4 13.1 12.6 13.2 
Others 18.7 19.9 20.7 19.2 17.4 17.6 19.4 19.2 20.4 17.7 
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8.8 8.5 8.7 12.2 9.3 7.9 9.2 10.3 8.8 12.2 
Urinary 
system 
6.5 6.0 5.5 6.7 6.9 6.8 5.9 7.4 5.9 6.9 
Cancer 
stage 
          
I 17.0 16.1 18.9 13.4 18.2 16.9 20.1 16.7 20.4 17.6 
II 21.6 21.1 19.6 17.4 22.2 22.4 18.6 15.5 19.5 18.9 
III 10.8 11.6 12.3 11.5 10.6 8.5 10.7 7.9 8.4 9.7 
IV 6.7 7.8 6.7 8.5 6.4 3.4 6.2 3.7 3.7 5.7 





          
No other 
condition 
12.9 18.2 2.7 4.4 7.6 11.0 1.0 2.2 1.0 1.0 
1 other 
condition 
23.0 26.9 22.9 21.7 18.6 23.1 10.8 14.5 15.0 10.8 
2 other 
conditions 
22.2 22.1 24.0 22.0 22.2 23.4 16.8 19.3 24.0 16.4 
3 other 
conditions 
16.6 14.3 17.8 17.6 19.0 17.4 20.7 19.3 21.2 18.8 
4 or more 
other 
conditions 
25.3 18.5 32.6 34.3 32.5 25.1 50.8 44.7 38.9 53.0 
 
*Percentage is column percentage for each of the parameters 
Hospitalizations and ED Visits According to the Characteristics of the Study Population 
    There was on average 0.57 hospitalization per person-year in cancer patients with a maximum 
value of 31.6 admissions per person-year, and 0.74 ED visits per person-year, and the highest value 
was 87.6 visits per person-year during the study period. Increasing age, male sex, rural residence, 
lower-income quintile, late-stage cancer, and lung and digestive system cancer were associated 
with a higher number of hospitalizations and ED visits. Patients with mood disorders had more 
hospitalizations and ED visits compared to those without mood disorders. In contrast, cancer 
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patients with arthritis had a higher number of ED visits but a lower number of hospitalizations per 
person-year than patients without arthritis (Table 2).    
Table 2. 
Hospitalizations and ED visits According to the Characteristics of the Study Population 
Characteristics Hospitalization 
PPY 
(Mean ± SD) 





Presence of mood 
disorders and arthritis 
 <0.0001  <0.0001 
No arthritis/mood 
disorders 
0.57 ± 0.92  0.66 ± 1.25  
Mood disorders only 
before cancer 
0.73± 1.06  1.03 ± 1.68  
Mood disorders only 
after cancer 
1.09 ± 1.33  1.20 ± 2.10  
Arthritis only before 
cancer 
0.61 ± 0.89  0.84 ± 1.37  
Arthritis only after 
cancer 
0.40± 0.62  0.61 ± 0.96  
Bothe the conditions 
before cancer 
 
0.86 ±1.12  1.39 ± 2.60  
Both the conditions 
after Cancer 
 
0.81 ± 1.10  1.20 ± 2.20  
Mood disorders before 
and arthritis after 
cancer 
0.58 ± 0.85  1.14 ± 1.64  
Arthritis before and 
mood disorders after 
cancer 
1.10 ± 1.30  1.37 ± 2.11  
Age Group  <0.0001  <0.0001 
18-44 0.40 ± 0.91  0.62 ± 1.22  
45-64 0.48 ± 0.87  0.66 ± 1.32  
>65 0.69 ± 0.89  0.83 ± 1.32  
Sex  <0.0001  <0.0001 
Male 0.62 ± 0.93  0.77 ± 1.39  
Female 0.53 ± 0.85  0.71 ± 1.24  
Income Quintile  <0.0001  <0.0001 
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Q1 0.65 ± 0.95  0.98 ± 1.72  
Q2 0.60 ± 0.91  0.81 ± 1.35  
Q3 0.58 ± 0.91  0.68 ± 1.13  
Q4 0.55 ± 0.87  0.61 ± 1.02  
Q5 0.51 ± 0.83  0.56 ± 0.95  
Ethnic Concentration  <0.0001  <0.0001 
Q1 0.64 ± 0.95  1.14 ± 1.81  
Q2 0.60 ± 0.91  0.98 ± 1.42  
Q3 0.56 ± 0.86  0.85 ± 1.21  
Q4 0.54 ± 0.86  0.78 ± 1.09  
Q5 0.52 ± 0.85  0.74 ± 1.03  
Place of Residence  <0.0001  <0.0001 
Rural 0.68 ± 1.03  1.26 ± 2.23  
Urban 0.56 ± 0.87  0.66 ± 1.07  
Type of Cancer  <0.0001  <0.0001 
Breast 0.34 ± 0.55  0.59 ± 0.98  
Colon and rectum 0.71 ± 0.90  0.78 ± 1.33  
Digestive system 
except for colon and 
rectum 
1.08 ± 1.23  1.11 ± 1.95  
Female genital 0.58 ± 0.91  0.72 ± 1.30  
Lung and bronchus 1.03 ± 1.09  1.17 ± 1.74  
Prostate 0.34 ± 0.53  0.57 ± 0.97  
Others 0.50 ± 0.89  0.69 ± 1.34  
Haematological 0.74 ± 1.18  0.85 ± 1.46  
Urinary system 0.73 ± 0.98  0.87 ± 1.35  
Cancer Stage  <0.0001  <0.0001 
I 0.37 ± 0.62  0.59 ± 1.06  
II 0.43 ± 0.67  0.63 ± 1.07  
III 0.79 ± 1.00  0.91 ± 1.47  
IV 1.17 ± 1.24  1.24 ± 1.90  
Unknown 0.58 ± 0.93  0.74 ± 1.34  
Number of Other 
Comorbidities 
 <0.0001  <0.0001 
0 0.37 ± 0.83  0.48 ± 1.06  
1 0.43 ± 0.81  0.57 ± 1.07  
2 0.44 ± 0.83  0.67 ± 1.23  
3 0.58 ± 0.85  0.78 ± 1.27  
4+ 0.87 ± 0.99  1.06 ± 1.63  
      
  Tables 2 shows that mood disorders were associated with significantly increased annual average 
hospitalizations and ED visits to cancer patients. Mood disorders diagnosed after cancer was 
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associated with higher average annual hospitalizations and ED visits compared to mood disorders 
diagnosed before cancer. Then again, arthritis when diagnosed before cancer was linked to 
substantially increased ED visits without much impact on hospitalizations. In contrast to mood 
disorders, arthritis when diagnosed after cancer was associated with both lower hospitalizations 
and ED visits. However, average annual hospitalizations and ED visits were quite high in cancer 
patients having both arthritis and mood disorders irrespective of the time of diagnosis of these 
conditions. HCU also increased with the co-occurrence of other chronic conditions. Among the 
other covariates, increased age, male sex, rural resident, digestive system cancer except for 
colorectal, lung cancer, and stage III and IV cancer were associated with higher utilization of health 
care services.  
Adjusted Impact of Arthritis and Mood Disorders on Hospitalizations of Cancer Patients 
     A negative binomial model was fitted to examine the impact of arthritis and mood disorders on 
the mean annual hospitalization of cancer patients adjusted for age, sex, place of residence, income 
quintiles, ethnic concentration, stage and type of cancer, and the number of other comorbidities 
(Table 3). 
Table 3. 
Adjusted Impact of Arthritis and Mood Disorders on the Hospitalization of Cancer Patients 
Adjusted for Sociodemographic and Clinical Variables 
Characteristics IRR 95% CI of IRR 
Presence of Arthritis and   
Mood Disorders (ref= no 
arthritis /mood disorders) 
Mood disorders only before cancer 1.19 1.14-1.24 
Mood disorders only after cancer 1.65 1.59-1.71 
Arthritis only before cancer 0.99 0.98-1.00 
99 




Characteristics IRR 95% CI of IRR 
Arthritis only after cancer 0.75 0.74-0.76 
Both arthritis and mood disorders 
before cancer 
1.25 1.20-1.29 
Both arthritis and mood disorders after 
cancer 
1.28 1.20-1.37 
Mood disorders before and arthritis 
after cancer 
1.01 0.92-1.10 
Arthritis before and mood disorders 
after cancer 
1.59 1.53-1.65 
Age Group (ref = 18-44) 45-64 1.02 1.01-1.04 
>=-65 1.21 1.19-1.23 
Sex (ref=female) Male 1.18 1.17-1.19 
Rural (ref = no) Yes 1.14 1.12-1.15 
Income Quintile (ref = Q1) 
  
Q2 0.95 0.94-0.96 
Q3 0.94 0.93-0.95 
Q4 0.91 0.90-0.92 
Q5 0.87 0.85-0.88 
Ethnic Concentration 
Quintile (ref = Q1) 
Q2 0.99 0.98-1.00 
Q3 0.96 0.94-0.97 
Q4 0.93 0.91 -0.94 
Q5 0.89 0.87-0.90 
Cancer Types (ref= others) Breast 0.82 0.80-0.83 
Colon and rectum 1.18 1.16-1.20 
Digestive system except colon and 
rectum 
1.83 1.80-1.86 
Female genital 1.36 1.33-1.39 
Hematological 1.29 1.27-1.31 
Lung and bronchus 1.55 1.53-1.58 
Prostate 0.57 0.56-0.58 
Urinary system 1.18 1.16-1.20 
100 




Characteristics IRR 95% CI of IRR 
Presence of other comorbid 
conditions (ref = no other 
conditions) 
1 other condition 1.07 1.05-1.09 
2 other conditions 1.18 1.17-1.20 
3 other conditions 1.34 1.32-1.37 
4 or more other conditions 1.91 1.88-1.94 
Cancer stage (ref = stage I) II 1.42 1.40-1.44 
III 2.04 2.00-2.07 
IV 2.87 2.82-2.92 
Unknown 1.50 1.48-1.53 
 
       Table 3 showed that the average annual number of hospitalizations was 19% greater in patients 
with mood disorders only present before cancer, while it was 65% higher among patients who 
developed mood disorders only after cancer, compared to patients without mood disorders and 
arthritis. In contrast, arthritis was associated with lower hospitalization whether it was developed 
before or after cancer. Cancer patients with both mood disorders and arthritis before and after 
cancer had 25% and 28% higher hospitalization rates respectively compared to those without any 
mood disorders or arthritis. Again, when cancer patients with arthritis had mood disorders 
developing after cancer, their hospitalization rates increased by 59% compared to those without 
any of the conditions. Older age groups, male sex, rural residents, and certain types of cancers 
were associated with an increased number of hospitalizations.  
    The interaction with other comorbidities was significant (results not shown), and stratified 
analysis according to MMB level was performed to examine whether the impact of arthritis and 
mood disorders on mean annual hospitalizations varied by the level of MMB (Table 4). The results 
showed that mood disorders alone occurring before cancer increased hospitalizations significantly 
when the patients had one or more other comorbid conditions. Mood disorders after cancer were 
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related to higher hospitalizations per person-year at all MMB level. The impact was highest when 
the patients had no other comorbid conditions but similar across all other MMB levels. On the 
other hand, the null impact of arthritis occurring before or after cancer was also comparable across 
the multimorbidity level (i.e. 1 condition, 2, 3, 4, or more conditions). The co-occurrence of mood 
disorders and arthritis after cancer increased hospitalizations the most when the patients had no 
other chronic conditions (Table 4).  
Table 4. 
Impact of Arthritis and Mood Disorders on the Hospitalization of Cancer patients by 
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*IRR adjusted for age, sex, residence, income, ethnic concentration, cancer type, stage, and the 
number of additional comorbidities. 
Adjusted Impact of Arthritis and Mood Disorders on the ED Visits of Cancer Patients 
     To examine the adjusted impact of arthritis and mood disorders on the ED visits of cancer 
patients, we also performed a negative binomial model. Table 5 showed that both arthritis and 
mood disorders were separately and jointly associated with increased emergency visits among 
cancer patients, except that arthritis alone occurring after cancer significantly decreased ED visits. 
When patients already had arthritis at the time of cancer diagnosis, mood disorders developing 
after cancer was associated with a 74% increased rate of ED visits, and when both the conditions 
developed before cancer, the rate of ED visits increased by 75%. 
Table 5. 
Impact of Mood Disorders and Arthritis on the ED Visits of Cancer patients Adjusted for 
Sociodemographic and Clinical Variables 
Characteristics IRR 95% CI of 
IRR 
Presence of Arthritis and   
Mood Disorders (ref = no 
arthritis/mood disorders) 
Mood disorders only before cancer 1.41 1.36-1.47 
Mood disorders only after cancer 1.55 1.49-1.61 
Arthritis only before cancer 1.20 1.19-1.21 
Arthritis only after cancer 0.97 0.96-0.98 
Both arthritis and mood disorders 
before cancer 
1.75 1.69-1.81 
Both arthritis and mood disorders 
after cancer 
1.60 1.50-1.69 
Mood disorders before and arthritis 
after cancer 
1.62 1.51-1.74 
Arthritis before and mood disorders 
after cancer 
1.74 1.68-1.81 
Age (ref = 18-44) 45-64 0.83 0.82-0.84 
>=65 0.85 0.84-0.87 
Sex (ref =female) Male 1.11 1.10-1.12 
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Rural (ref = no) Yes 1.63 1.62-1.65 
Income Quintile (ref =Q1) 
 
Q2 0.90 0.89-0.91 
Q3 0.86 0.85-0.87 
Q4 0.82 0.81-0.83 
Q5 0.76 0.75-0.77 
Ethnic Concentration 
Quintile (ref = Q1) 
Q2 0.93 0.92-0.94 
Q3 0.86 0.85-0.87 
Q4 0.78 0.77-0.79 
Q5 0.68 0.67-0.69 
Cancer Types (ref = others) Breast 0.96 0.94-0.97 
Colon and rectum 1.01 0.99-1.02 
Digestive system except colon and 
rectum 
1.50 1.47-1.52 
Female genital 1.17 1.15-1.19 
Hematological 1.13 1.12-1.15 
Lung and bronchus 1.37 1.35-1.39 
Prostate 0.76 0.74-0.77 
Urinary system 1.09 1.07-1.10 
Presence of other comorbid 
conditions (ref= no other 
conditions) 
1 other condition 1.18 1.16-1.20 
2 other conditions 1.37 1.35-1.39 
3 other conditions 1.56 1.54-1.59 
4 or more other conditions 2.06 2.03-2.10 
Cancer stage (ref = stage I) II 1.20 1.18-1.22 
III 1.53 1.51-1.55 
IV 2.05 2.01-2.08 
Unknown 1.23 1.21-1.24 
 
   We tested the interaction between arthritis, mood disorders, and other comorbid conditions in 
the model. Though the interaction was significant, stratified analysis by multimorbidity level 
showed that the differences in risk ratios of ED visits were related to the main exposure rather than 
MMB levels. As such, there were differences in the impact of arthritis and mood disorders on ED 
visits, but this impact remained similar within the level of comorbidities. Mood disorders increased 
the risk of ED visits more compared to arthritis and the difference was larger when the patients 
had no or one other chronic condition. The presence of both mood disorders and arthritis before 
and after cancer was associated with an increased risk of ED visits at all multimorbidity levels 
(Table 6).  
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Impact of Arthritis and Mood Disorders on ED Visits Stratified by the Number of Other 
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     The study evaluated the impact of mood disorders and arthritis on the health care utilization by 
cancer patients as measured by hospitalizations and ED visits per person-year. The study findings 
showed that mood disorders were associated with increased hospitalizations and ED visits among 
cancer patients irrespective of developing before or after cancer. This finding was in alignment 
with the previous research (Mausbach & Irwin, 2017; Niazi et al., 2018). Niazi et al. (2018) found 
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that multiple myeloma patients with depression had a 41% higher risk of inpatient admission and 
37% increased risk of ED visits (Niazi et al., 2018). In contrast, we found a 65% higher risk of 
hospitalizations and a 55% higher risk of ED visits in cancer patients diagnosed with mood 
disorders after cancer. Besides, mood disorders diagnosed before cancer was also associated with 
19% more hospitalizations and 41% more ED visits.  Niazi et al. (2018) conducted their study 
within the Medicare beneficiaries of the United States, who were older and, they included patients 
with a specific type of blood cancer, i.e. multiple myeloma whereas, we included all the patients 
with cancer diagnosed within a specified period. They identified the patients with a specific mood 
disorder i.e. depression and they did not account for the time of development of the condition 
(before/after cancer). Moreover, they only considered whether the patients had hospitalizations 
and ED visits without considering the number of visits. This might explain the discrepancy in the 
risk of ED visits between their study and our study.  Mausbach & Irwin (2017) found that 
depression in cancer patients was associated with a 76% higher rate of health services visits 
(Mausbach & Irwin, 2017). Here the authors included all the visits to the different health services 
providers including hospital admissions and ED visits. Depressed cancer patients had 2.45 times 
higher odds of ED visit and 1.81 times higher odds of at least one hospitalization in one year 
compared to the non-depressed patients (Mausbach & Irwin, 2017). However, in calculating the 
risk of hospitalization and ED visits, encounters with the health services in the first year of cancer 
diagnosis were taken into account without considering the actual number of hospitalizations or ED 
visits. As HCU is generally higher in the first year of cancer diagnosis, Mausbach & Irwin (2017) 
found a higher odds ratio of HCU associated with depression.  
    On the other hand, arthritis alone when diagnosed before cancer was associated with 20% 
increased ED visits among cancer patients while having no impact on hospitalizations. However, 
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when arthritis was diagnosed after cancer it was related to lower hospitalizations and ED visits. 
Wright et al. (2010) found that patients with knee osteoarthritis had more annual emergency visits, 
hospitalizations, and physician visits compared to those without osteoarthritis, and the HCU 
increased with the presence of comorbidities including cancer (Wright et al., 2010). This was in 
contrast with our findings, with regards to both hospitalizations and ED visits. The study by Wright 
et al. (2010) included the general population without cancer and described that most of the 
hospitalizations in arthritis patients were due to joint replacement (Wright et al., 2010). As cancer 
patients were mostly in severe condition and joint replacement is unlikely among them, arthritis-
related hospitalizations should be lower in cancer patients with arthritis. Moreover, the 
development of arthritis and the associated pain might lead to an increased encounter with the 
primary care physicians which has been shown to decrease hospitalizations and ED visits (Mileski 
et al., 2020; Rosano et al., 2013; Shi, 2012). Arthritis in combination with mood disorders before 
or after cancer was associated with higher hospitalizations per person-year in comparison to the 
cancer patients without arthritis and mood disorders. Interestingly, when cancer patients diagnosed 
with mood disorders before their cancer developed arthritis, there was no increase in 
hospitalizations. On the contrary, the development of mood disorders after cancer in patients with 
cancer and arthritis led to a 59% increase in hospitalizations.  So, mood disorders alone or in 
combination with arthritis were related to higher hospitalization in cancer patients. It can be 
assumed that the development of a new psychological condition in cancer patients might increase 
health care utilization as evidenced by literature (McDermott et al., 2018). 
    We performed a stratified analysis by the level of MMB and found that the impact of mood 
disorders diagnosed before cancer on hospitalizations was highest in patients having one or more 
co-occurring conditions. These findings were in alignment with previous evidence that the 
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comorbidity index was a significant predictor of HCU including hospitalizations and ED visits in 
cancer patients with depression (Mausbach & Irwin, 2017). The association between mood 
disorders after cancer and hospitalizations was most pronounced in patients with no other 
comorbidities and similar across all other MMB level. On the other hand, arthritis alone when 
diagnosed after cancer was associated with lower hospitalizations and ED visits across all MMB 
level. In complex cancer patients, the pain associated with arthritis might be misattributed as the 
pain of cancer and as such, health services use might be largely due to cancer and other 
comorbidities. While considering the joint effect of arthritis and mood disorders on HCU, our 
study showed that the impact of mood disorders and arthritis developing before cancer on HCU 
did not vary statistically among the different MMB levels. Arthritis and mood disorders together 
developing after cancer were associated with highest increase in HCU among the patients with no 
other comorbidities. In cancer patients with MMB, any increase in hospitalizations and ED visits 
might be mostly attributed to cancer or other severe chronic conditions rather than arthritis and 
mood disorders. One finding from the study showed that when arthritis developed after cancer in 
patients with mood disorders before cancer, and without any other comorbidities, there was three 
folds increase in hospitalizations.  Perhaps, the newly diagnosed arthritis and the associated pain 
was associated with increased hospitalization as these patients were devoid of any other 
comorbidities and any new symptoms were attributed to their hospitalizations. We also found that 
hospitalizations and ED visits were higher among elderly patients, males, rural residents, and in 
patients with late-stage cancer. These findings are consistent with the results of the previous study 
(Lash et al., 2017).  
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Strengths and Limitations 
      The study is mainly limited because of the operationalization of exposure. We considered the 
presence of mood disorders and arthritis as exposure without accounting for the time of occurrence 
when developing after a cancer diagnosis. So, some patients might develop these conditions after 
the outcome, i.e. hospitalizations and ED visits, and thus this would not be responsible for their 
HCU. However, the distinction between diagnosis before and after cancer is key. As most of the 
patients developed their mood disorders and arthritis before their cancer and HCU were counted 
after the cancer diagnosis, a temporal relationship could be established between arthritis, mood 
disorders, and HCU. Moreover, the mean time of development of mood disorders and arthritis 
after cancer was much lower than the mean follow-up period. So, it was expected that the diagnosis 
of mood disorders and arthritis would contribute towards the HCU of most patients. Still, there 
would be some misclassification of the exposure definition which would certainly over-estimate 
the impact of mood disorders and arthritis on the HCU of cancer patients.  
   The study was a secondary analysis of data from health administrative databases and included 
only those patients having contact with the health care system contributing to potential selection 
bias. However, the sample was large enough to get a robust estimate of long term HCU by cancer 
patients. Other limitations are related to the predictor’s measurement. The cases of arthritis, mood 
disorders, and other chronic conditions were identified using administrative databases, which may 
contribute to the misclassification of these conditions in cancer patients. In administrative 
databases, there are possible errors in coding conditions as well as these databases show little 
difference in coding complicacy of a condition with comorbidities (Mazzali et al., 2016). This 
might result into misclassification leading to higher count and impact of comorbities on the study 
outcomes. In OHIP, there are three codes for mood disorders, namely 296 (episodic mood 
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disorders), 300 (cyclothymic disorder), and 311 (Depressive Disorder NOS). We included only 
296 from OHIP and ICD-10 codes from DAD and NACRS for identifying mood disorders. 
Moreover, under-reporting of psychiatric conditions and other comorbidities in cancer patients 
may also lead to misclassification bias although linking several databases enabled us to 
appropriately measure the prevalence of the chronic conditions. Moreover, Canadian 
administrative databases have 85% accuracy for diagnostic codes (Juurlink et al., 2006). So, using 
administrative databases could under estimate the prevalence of chronic conditions causing 
dilution of their impact on health care utilizations.  
   In this study, only 16 chronic conditions excluding arthritis and mood disorders were used to 
define MMB which creates a chance for misclassifying the cancer patients according to MMB 
level. There are other severe chronic conditions like congenital anomalies, thyroid diseases, 
glaucoma which were not taken into account in the study due to the unavailability of data. 
However, literature suggested that including 11 or 12 conditions is optimum for obtaining the 
population prevalence of MMB, and adding more conditions only increases complexity 
(Diederichs et al., 2011; Fortin et al., 2012; van den Akker et al., 1998).  We also only counted the 
number of conditions and did not account for severity, whereas one severe condition might impact 
HCU more than having two or three less severe conditions.  
     Despite the limitations, the study had many strengths too. It was a population-based 
retrospective cohort study. Although there was some misclassification in defining the exposure, 
we were able to establish a temporal relationship between arthritis, mood disorders, and health 
services use in cancer patients specifically among the patients who were diagnosed with those 
conditions before cancer. The study was conducted with health administrative data including all 
the adult patients with cancer in Ontario, and we got an estimate of hospitalization and ED visits 
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in cancer patients at the population level. Canadian health administrative databases have extremely 
high data coverage and accuracy (Juurlink et al., 2006). Mood disorders, arthritis, and other 
comorbidities included in the study were defined using algorithms based on administrative 
databases widely cited in the literature to address MMB where applicable or two physicians’ visit 
in a two years period or one hospital admission (Austin et al., 2002; Fiest et al., 2014; A. S. 
Gershon et al., 2009; Andrea S Gershon et al., 2009; Hux et al., 2002; Jaakkimainen et al., 2016; 
Schultz et al., 2013; Widdifield et al., 2014). 
     We performed a stratified analysis by the number of comorbidities to observe whether the 
association between arthritis, mood disorders, and HCU was modified by the number of other co-
occurring conditions. We found that the association between arthritis, mood disorders, and HCU 
varied by the time of occurrence of mood disorders and arthritis (before/after cancer) as well as by 
the multimorbidity level. However, mood disorders diagnosed before or after cancer was 
associated with a higher increase of HCU than arthritis. Besides, in complex cancer patients, the 
number of co-occurring conditions was an important predictor of higher use of health services. 
This explained the importance of addressing MMB, specifically mood disorders in cancer patients 
to decrease their use of health services. The patients were diagnosed with cancer at a different time 
and entered the cohort as soon as they were diagnosed with cancer. As a result, the follow-up time 
was different for each patient and between 5-15 years or more. So we calculated the average annual 
health care utilization accounting for hospitalization and ED visits per person-year. The long 
follow-up period provided a large window to assess whether mood disorders and arthritis have an 
impact on health care utilization. It has been shown that the duration and chronicity of depressive 
symptoms is an important predictor of increased health services use (Roberts et al., 2018). In our 
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study, we followed the patients for a longer period which might enable us to better understand the 
impact of mood disorders and arthritis on the health care utilization of cancer patients. 
Implications of the Findings 
      The study revealed that mood disorders were associated with both increased hospitalizations 
and ED visits significantly in cancer patients while arthritis was linked to only increased ED visits 
but decreased hospitalizations. The retrospective cohort study could establish a temporal 
relationship between arthritis, mood disorders, and HCU and as we looked at the average annual 
hospitalizations and ED visits for a substantial period of time at the population level, it enabled us 
to generate and test our hypotheses on the potential role of MMB including arthritis and mood 
disorders on the HCU of cancer patients. We hypothesized and our study provided evidence that 
multimorbidity including arthritis and mood disorders is associated with greater use of health 
services in cancer patients. The study also revealed that the impact of arthritis and mood disorders 
did not vary significantly across all the levels of multimorbidity; however, mood disorders 
occurring after cancer increased HCU most when the patients had one or more other comorbidities. 
On the other hand, arthritis alone or in combination with mood disorders was associated with with 
higher HCU when the patients had no other chronic conditions. Then again, both hospitalizations 
and ED visits in cancer patients increased with the number of co-occurring conditions. These 
findings show the importance of addressing MMB, especially mood disorders to decrease  HCU 
that may be avoidable in cancer patients. The findings from the study add to the literature and 
helped to understand the predisposing factors for higher HCU in cancer patients. Future 
prospective cohort studies on the impact of MMB on the HCU and identifying the specific chronic 
conditions or disease clusters causing higher HCU will enable us to focus on the complex cancer 
patients having the highest health care needs. Long-standing conditions in patients with cancer 
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need to be addressed early and proper management of the chronic conditions will decrease their 
health service use and eventually improve patients’ quality of life while reducing the burden on 
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Appendix A: Administrative Databases Used in the Study and the Corresponding Variables 





Includes data on all person eligible for the 
Ontario Provincial Health care program and 
provides demographic information like age, 
sex, date of birth, death, residence, and 
neighborhood income 






Hospital inpatient data. It includes data on 
hospital admission, discharge, length of 
stay, primary diagnosis, other diagnoses, 
procedures, and interventions 
Arthritis, mood disorders, and 
other comorbidities using the 





Physician’s claim database. Includes the 
date of visit, diagnosis, procedures such as 
laboratory tests and vaccination 
Arthritis, mood disorders, and 
other comorbidities using the 





Includes hospital outpatient data, diagnosis, 
day surgeries, and Emergency department 
visits 
Arthritis, mood disorders, and 
other comorbidities using the 
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ICD codes, date/year of 
diagnosis, ED visits 
Ontario Cancer 
Registry (OCR) 
Provincial database of all the residents of 
Ontario having a diagnosis of cancer. 
Contains demographic and clinical 
information including the date of diagnosis, 
primary cancer site, cancer stage, and death 
Age, sex, date of birth, death, 






The Ontario Marginalization Index is a 
measure of inequalities between the 
geographical areas based on four 
dimensions; residential instability, material 
deprivation, ethnic concentration, and 
dependency 















Appendix B: ICD Codes for Chronic Conditions 
Condition ICD 9 / OHIP ICD 10 
AMI 410 I21, I22 
Arthritis – Osteoarthritis 715 M15-M19 
Arthritis - Other Arthritis 
(Synovitis, Fibrositis, 
Connective tissue disorders, 
Ankylosing spondylitis, Gout 
Traumatic arthritis, pyogenic 
arthritis, Joint derangement, 
Dupuytren’s contracture, 
Other MSK disorders) 
727, 729, 710, 720, 274, 716, 
711, 718, 728, 739 
M00-M03, M07, M10, M11-
M14, M20-M25, M30-M36, 
M65-M79 




Asthma 493 J45 
Cancer 140-239 C00-C26, C30-C44, C45-C97 
Cardiac Arrythmia 427.3 (DAD) / 427 (OHIP) I48.0, I48.1 
CHF 428 I500, I501, I509 
COPD 491, 492, 496 J41, J43, J44 
Dementia 
290, 331, 797 (OHIP) / 290.0, 
290.1, 290.3, 290.4, 290.8, 
F000, F001, F002, F009, 
F010, F011, F012, F013, 
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290.9, 294.1, 294.8, 294.9, 
331.0, 331.1, 331.2, 797 
(DAD) 
F018, F019, F020, F021, 
F022, F023, F024, F028, F03, 
F051, F065, F066, F068, 
F069, F09, G300, G301, 
G308, G309, G310, G311, 
R54 
Mood Disorders 296 F30-F34, F38, F39 
Diabetes 250 E08 - E13 
Hypertension 401, 402, 403, 404, 405 I10, I11, I12, I13, I15 
Osteoporosis 733 M81 M82 
Renal failure 403, 404, 584, 585, 586, v451 
N17, N18, N19, T82.4, 
Z49.2, Z99.2 
Stroke 430, 431, 432, 434, 436 I60-I64 
Coronary syndrome 
(excluding MI) 411-414 I20, I22-I25 
Other mental disorders 
(substance use disorder, 
psychotic disorder, anxiety, 
stress reaction-specifically 
PTSD, personality disorder) 
291, 292, 303, 304, 305, 295, 
298, 297, 300, 308, 301 
F10-F19, F55, F20-F29, F40-












Univariate Analysis of Time to Mood Disorders, Arthritis, Follow-up Time and Time to 
Death in Patients with Mood disorders and Arthritis Developing after Cancer (in days) 










Time to diagnosis of 
mood disorders 
1178.66 1009.12 357 881 1786 42 
Time to the end of the 
study (follow up time for 
the living patients) in 
patients with mood 
disorders 
3791.38 1013.60 2945 3834 4677 2760 
Time to death (follow up 
time for the patients who 
died during the study 
period) in patients with 
mood disorders 
1919.83 1186.59 896 1677 2739 874 
Time to diagnosis of 
arthritis 
1252.37 967.52 466 1010 1842 385 
Time to the end of the 
study (follow up time for 
the living patients) in 
patients with arthritis 
3951.57 993.60 3172 4069 4809 5112 
Time to death (follow up 
time for the patients who 
died during the study 
period) in patients with 
arthritis 




































     The purpose of this thesis is to study whether there is an association between arthritis and the 
development of mood disorders in cancer patients considering the level of multimorbidity and to 
examine the impact of arthritis and mood disorders on their health care utilization. The findings 
showed that arthritis was not associated with the risk development of mood disorders in cancer 
patients; rather, the number of other comorbidities had a significant impact. However, the null 
association between arthritis and mood disorders did not alter in the presence of other co-occurring 
conditions. Another key finding was that cancer patients with both arthritis and mood disorders 
experienced higher HCU and mood disorders were associated with the highest increase in HCU.  
6.1 Main Findings 
6.1.1 The Incidence of Mood Disorders in Cancer Patients was 16.9 per 1000 and did not Vary 
According to the Presence of Arthritis 
     The crude cumulative incidence of mood disorders in the study population was 16.9 (95% CI 
16.6-17.3) per 1000. The incidence was similar among patients with or without arthritis 
(17.0/1,000 vs. 16.8/1,000). Most of the studies looked at the prevalence of mood disorders but 
there is limited evidence in the literature on the incidence of mood disorders in cancer patients 
(Hung et al., 2013; Zhu et al., 2017). Hung et al. (2013) followed up a cohort of breast cancer 
patients in Taiwan and found that the incidence of mood disorders in these patients was 196/1,000 
population which was higher than our study’s estimate. They defined mood disorders with ICD-9 
codes and included anxiety with mood disorders causing a much higher estimate than our study 
(Hung et al., 2013). On the other hand, Zhu et al. (2017) calculated the incidence of mood disorders 
among cancer patients in Sweden as  13.99 per 1,000 population which was slightly lower than 
our result as they considered only major depressive disorder. 
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    Our study showed that arthritis was not associated with an increased risk of mood disorders in 
cancer patients. This contrasted with our hypothesis where it was assumed that arthritis would 
increase the risk of mood disorders in cancer patients. In previous research, there were no explicit 
tests of increased risk of mood disorders associated with arthritis among cancer patients 
specifically. However, cancer and arthritis were individually implicated as risk factors for mood 
disorders in the literature (He et al., 2008; Hung et al., 2013; Jeong et al., 2017). Among breast 
cancer patients, the incidence of mood disorders was 33% higher than those without cancer (Hung 
et al., 2013).  Specifically, breast cancer patients had a two times higher risk of developing major 
depressive disorders and bipolar disorders (Hung et al., 2013). This was a unique finding in this 
study as most other studies found an increased risk of depression in cancer patients while this study 
also reported a higher incidence of bipolar disorder. The authors discussed that hormones used in 
breast cancer treatment as well as genetic mutation could increase the risk of bipolar disorders 
among these patients (Hung et al., 2013). On the other hand, van ’t Land et al. (2010)  found a 1.9 
times higher risk of developing mood disorders in patients with arthritis (van ’t Land et al., 2010).  
Hsu et al. (2014) reported two folds higher incident rates of bipolar disorder in patients with 
rheumatoid arthritis. The authors described that the inflammatory process of joints involved in 
rheumatoid arthritis might be associated with the inflammation of the brain, eventually increasing 
the risk of developing bipolar disorders (Hsu et al., 2014; Lampa et al., 2012). We found a null 
association between arthritis and the development of mood disorders in cancer patients. One 
possible explanation for our results may be that the pain associated with arthritis and the severity 
of cancer might cause a misattribution of the symptoms of depression and other mental conditions. 
Moreover, there might be overlapping of symptoms, i.e. pain is common in both cancer and 
arthritis; as such, depression associated with pain could be attributed mostly to cancer rather than 
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arthritis. Another possibility is inadequate care about the mental health of cancer patients and 
ignoring their psychiatric symptoms. When stratified by cancer types, patients with lung, prostate, 
and urinary system cancers showed a higher risk of mood disorders associated with arthritis at the 
baseline while breast cancer patients with arthritis showed a lower baseline risk. The impact of 
arthritis on the development of mood disorders decreased with time in the lung, prostate, and 
urinary system cancer, while the impact of arthritis increased in breast cancer patients with time. 
In cancers with poor prognosis, i.e. lung cancer, depression is mostly associated with the adverse 
outcomes of the cancer. Chronic conditions like arthritis could become less important with the 
advancement of cancer and might not increase the risk of mood disorders including depression 
among these patients. In contrast, breast cancer patients generally had longer survival, and likely 
to suffer from arthritis for a longer time. Suffering from arthritis for substantial time leads to 
disability, dependence on others, and eventually depression (Nicassio, 2010). This can possibly 
explain the higher impact of arthritis on the development of mood disorders over time. 
Nevertheless, Hung et al. (2013) found no association between autoimmune diseases, namely 
arthritis and mood disorders over time in their population-based cohort study on breast cancer 
patients in Taiwan (Hung et al., 2013).  
6.1.2 The Number of Chronic Other Chronic Conditions (Multimorbidity) Constitutes an 
Important Factor for Mood Disorders Occurrence but does not Modify the Adjusted Impact of 
Arthritis 
   The risk of mood disorders in cancer patients increased with the multimorbidity level. This was 
consistent with the previous literature where the risk of depression was shown to be increased with 
the number of chronic conditions (Hartung et al., 2017; Massie, 2004). In a population-based study 
conducted in the United States, the authors reported increased odds of developing depression in 
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breast cancer patients with comorbidities and the risk was highest among those with four or more 
chronic conditions (Zoorob et al., 2019). However, stratified analyses by the number of co-
occurring conditions showed that arthritis had no impact on the development of mood disorders, 
and this did not change whether the patients with cancer had no other conditions or one or more 
chronic conditions. 
     Among the other covariates increased age, stage IV cancer, certain cancer types, and death 
during the study period were significant risk factors for mood disorders. Similar results had been 
found in the literature (Nikbakhsh et al., 2014; Walker et al., 2014; Zoorob et al., 2019). 
Interestingly, in our study, male sex was linked to higher risk of mood disorders in contrast to 
literature where females are more likely to develop mood disorders (Caruso et al., 2017). However, 
the proportion of patients with two or more conditions was higher among males than females. 
Research showed that MMB is a known risk factor for the development of depression (Zoorob et 
al., 2019) and this could explain the higher risk of developing mood disorders among the males 
after adjusting for confounders. In our study, the crude incidence of mood disorders was higher 
among the age group 18-44 but when adjusted for other covariates, older age groups became a 
significant factor for developing depression. There are controversial findings in the literature 
regarding the impact of age on the risk of mood disorders. Nikbakhsh et al. (2014) reported that 
depression was more common among elderly people whereas Walker et al. (2014) described 
younger age as a risk factor for developing depression (Nikbakhsh et al., 2014; Jane Walker et al., 
2014). Our study results followed the findings of Nikbakhsh et al. (2014) who were also focusing 
on cancer patients specifically.  
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6.1.3 Mood Disorders and Arthritis was Associated with Increased the Hospitalizations and 
ED Visits in Cancer Patients and Mood Disorders had Higher Impact on HCU than Arthritis 
   Both arthritis and mood disorders were associated with increased HCU in cancer patients. Cancer 
patients with arthritis diagnosed before cancer exhibited 20% (95% CI = 19-21%) more ED visits 
but slightly less hospital admission. Again, post-cancer diagnosis of arthritis was associated with 
lower hospitalizations and ED visits per person-year. On the other hand, pre-cancer diagnosis of 
mood disorders was linked to 19% (95% CI = 14-24%) more hospitalizations and 41% (95% CI = 
36-47%) more ED visits. Then again, mood disorders diagnosed after cancer were related to higher 
increase in both hospital admissions (65%; 95% CI = 59-71%) and ED visits (55%; 95% CI = 49-
61%). When arthritis and mood disorders were present together before cancer, there was an 25% 
(95% CI = 20-29%) increase in hospitalizations and 60% (95% CI = 50-69%) increase in ED visits 
respectively. Furthermore, the co-occurrence of arthritis and mood disorders after cancer led to 
28% (95% CI = 20-37%) greater hospitalizations and 60% (95% CI = 50-69%) more ED visits.  
The study findings are in alignment with the previous literature to some extent (Himelhoch et al., 
2004b; Mausbach & Irwin, 2017; McDermott et al., 2018). Mausbach & Irwin (2017) mentioned 
from their population-based study that depression increased the risk of ED visits by 3.05 times and 
at least one hospitalization in one year by 2.24 times (Mausbach & Irwin, 2017). Niazi et al. (2018) 
found that mood disorders were associated with 41% more hospitalizations, 37% higher ED visits, 
and 22% higher ambulatory service usage. A previous study found that pre-existing depression in 
cancer patients decreased HCU in comparison to patients without depression whereas, depression 
diagnosed after cancer had no statistically significant impact on HCU (McDermott et al., 2018). 
We found that mood disorders was associated with increased HCU in cancer patients irrespective 
of its time of development (before/after cancer). McDermott et al. (2018) considered only older 
131 




lung cancer patients with increased disease severity and lower survival. As such, they could not 
find a significant association between depression and HCU. Our study was a population-based 
study with a large sample including all the cancer patients surviving at least a year and yielded a 
significant impact of mood disorders diagnosed before and after cancer on the HCU of the patients. 
     Interestingly hospitalization was lower in patients with arthritis only and a possible hypothesis 
is that cancer patients with arthritis had frequent encounters with the health care system, 
particularly primary care. Research showed that primary care physicians and nurse practitioners 
could have a potential impact on decreasing hospital admission and ED visits in patients with 
various chronic conditions (Mileski et al., 2020; Rosano et al., 2013; Shi, 2012). In cancer patients 
with arthritis, the early diagnosis of complications and initiation of treatments at the primary care 
level could prevent further hospitalizations and ED visits. However, arthritis diagnosed before 
cancer was linked to higher ED visits. The disease process of arthritis follows a chronic 
inflammatory course, having arthritis for a longer time could lead to uncontrolled symptoms and 
eventually increase ED visits significantly.  
6.1.4 The Impact of Arthritis and Mood Disorders on the HCU of Cancer Patients Varied by 
the Level of Multimorbidity. Mood disorders was associated with highest Increase in 
Hospitalizations in Patients Without any Co-occurring Conditions while Most Pronounced 
Impact for ED visits was Found among the Patients with One or More Chronic Conditions. 
      Stratified analyses by the level of multimorbidity showed that the impact of mood disorders 
before cancer on hospitalization was similar among the patients having none or one or more 
comorbidities. When mood disorders alone were diagnosed after cancer hospitalizations were 
highest when the patients had no other comorbidities but remained similar for one or more co-
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morbidities. In complex cancer patients with multiple chronic conditions, hospital admissions 
might be related to other conditions rather than mood disorders. There might be misclassification 
bias as psychological conditions are generally under-reported in cancer patients resulting in 
dilution of the estimate of the impact of mood disorders at higher MMB levels.  However, 
diagnosis of mood disorders was linked to increased ED visits similarly at all MMB level.   
     On the other hand, the impact of arthritis on the hospitalizations and ED visits of cancer patients 
was similar across levels of MMB. When mood disorders and arthritis both occurred either before 
or after cancer, there was a significant increase in hospitalizations and ED visits at all MMB levels. 
This explained that the impact of arthritis and mood disorders were mainly related to the main 
exposure and time of occurrence (before and after cancer) rather than the number of other 
comorbid conditions. However, MMB level (excluding arthritis and mood disorders) was a 
significant risk factor for hospitalization and ED visits. This finding was consistent with the results 
of the previous studies (Himelhoch, et al., 2004; Pitman et al., 2018; Roy et al., 2018). Literature 
suggested that the number of comorbidities was associated with HCU in cancer patients and an 
increasing number of comorbidities including arthritis and mood disorders increased ED visits in 
cancer patients (Johansson et al., 2004). Wright et al. (2010) found that cancer patients with 
different chronic conditions need more health care services compared to those without any 
comorbidities and the need for HCU increased with the number of chronic conditions which was 
similar to our study findings (Wright et al., 2010).  
6.2 Limitation of the Study 
       The use of administrative data to diagnose the cases of arthritis and mood disorders was the 
main limitation of the study. Diagnosis of chronic conditions based on administrative data might 
cause misclassification bias. The participants in the study were cancer patients diagnosed between 
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2003-2013, surviving more than a year, and having contacts with the health care system. As we 
only included the patients having a valid health card, there was a chance of selection bias. The 
patients who survived less than a year were excluded to avoid reverse causality but that could lead 
to an underestimation of the incidence of mood disorders. We performed a sensitivity analysis to 
describe the association between arthritis and mood disorders in cancer patients surviving less than 
a year. The findings showed that arthritis and MMB were not linked to the risk of mood disorders 
in these patients. They had increased disease severity, and their depression was associated 
primarily with the worst prognosis of their cancer. As a result, arthritis, MMB, and other covariates 
did not have an impact on the risk of mood disorders in these cancer patients.  
    In cancer patients, due to the severity of the disease, other chronic conditions might be under-
reported. So, there could be a possible underestimation of the incidence of mood disorders. 
Moreover, we are considering depression and bipolar disorder together as mood disorders while 
the pathological process and risk factors are different for those two types of mood disorders. 
Literature showed that cancer and arthritis are risk factors for depression while there is little 
evidence for their impact on the development of bipolar disorders (Hartung et al., 2017; Rathbun 
et al., 2018). We were not able to consider these two conditions separately in our database which 
might decrease the impact of arthritis on developing mood disorders. However, as the population 
prevalence of bipolar disorders is generally low (McDonald et al., 2015), it should not impact the 
study findings significantly. To determine MMB in cancer patients, only 16 chronic conditions 
were included in the study. The patients might have other comorbidities that were not included in 
the study leading to an underestimation of the burden of MMB. Moreover, the time of diagnosis 
of the chronic conditions was not taken into account which created misclassification of 
multimorbidity level diluting the impact of MMB on the development of mood disorders.  
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     To assess the impact of arthritis and mood disorders on the HCU of cancer patients, we adopted 
a retrospective cohort study design. We considered that all the cases of mood disorders and arthritis 
were diagnosed before the outcomes (hospitalizations and ED visits per person-year). In fact, 
among the patients who were diagnosed with arthritis or mood disorders after their cancer might 
encounter the health care system before they developed those conditions. These patients were 
misinterpreted as exposed while they were actually not exposed. Thus, there was certainly some 
over-estimation of arthritis and mood disorders and associated HCU. However, as the average time 
for the development of mood disorders and arthritis was much lower than the average follow-up 
time, we expected that most patients developed mood disorders and arthritis well before to impact 
their HCU. The study did not consider the severity or type of chronic conditions while one severe 
condition could cause higher HCU than two or more less severe conditions. There were 
unmeasured confounders that were not considered in the study due to the unavailability of data. 
6.3 Strengths of the Study 
     The first part of the thesis was a population-based retrospective cohort study that provided 
evidence for the temporal association between arthritis and mood disorders in cancer patients. We 
used the provincial administrative database, namely DAD, OHIP, NACRS for identifying chronic 
conditions including arthritis and mood disorders. An ICES investigative report on the Discharge 
Abstract Database described that the accuracy of demographic information was 97%, and 
diagnostic codes were 85% (Juurlink et al., 2006). In detecting the cases of rheumatoid arthritis, 
the Canadian administrative databases have 75-90% sensitivity, and 51-83% positive predictive 
value based on the algorithm used (Widdifield et al., 2014). The follow-up period for the cohort 
study was between 5-15 years and we could get long-term incidence rates of mood disorders and 
HCU in cancer patients. For classifying MMB level, 16 chronic conditions were considered 
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whereas previous evidence showed that including 11 or 12 conditions are optimum to get 
population prevalence of MMB (Diederichs et al., 2011; Fortin et al., 2012; van den Akker et al., 
1998).  
    The retrospective cohort study assessing the association between arthritis, mood disorders, and 
HCU provided an estimate of the average annual HCU in cancer patients. The study also provides 
evidence for the temporal relationship between arthritis, mood disorders, and HCU in cancer 
patients and tested our hypothesis that MMB including mood disorders and arthritis increased 
HCU. We considered the time of diagnosis of mood disorders and arthritis and could demonstrate 
the differential impact of these conditions on the HCU of cancer patients when they developed 
alone or in combination before and after cancer. Stratified analyses were performed to see whether 
the association between arthritis, mood disorders, and HCU varied by the level of MMB and by 
different cancer types. Thus, we could identify the patients most probable of developing mood 
disorders as well as more likely to have higher HCU.  
6.4 Epidemiological Implications: Internal and External Validity 
       In the first part of the study, we assessed the impact of arthritis on the development of mood 
disorders in cancer patients. In the second part, we examined the association between arthritis, 
mood disorders, and HCU of cancer patients. We identified patients with mood disorders using 
ICD-10 codes from DAD and NACRS and ICD-9 codes from OHIP. In OHIP there were three 
codes for mood disorders and among them, we considered the code specific for mood disorders. 
Besides, mood disorders were also identified using ICD-10 codes in hospitalizations data (DAD 
and NACRS). So, we most certainly achieved high specificity in the study while there was an 
underestimation of the incidence and prevalence of mood disorders in cancer patients. The 
prevalence of mood disorders estimated in the study was 3.52% which was much lower than the 
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annual prevalence of mood disorders (9%) in Canada in 2019 (Statistics Canada, n.d.).  As only 
the codes specified for mood disorders were included in the study, the study might have less 
sensitivity while having high specificity. On the other hand, DAD has an accuracy of 85% for 
diagnostic codes which could decrease the sensitivity and specificity of the study as well (Juurlink 
et al., 2006).  
      The study population includes only those adult patients with cancer who had contacts with the 
health care system. Canada has a universal health care system, and OHIP provides health coverage 
to all the residents in Ontario, including the immigrants after their three months of the mandatory 
waiting period. As the study was population-based, so the selection bias was minimal and 
adjustment for main confounders contributed to good internal validity. The study analyzed data at 
the provincial level, and Ontario has the highest population in Canada. The findings of the study 
will apply to the Canadian population having similar access to the health care system as well as 
other high-income countries with comparable socio-demographic characteristics and healthcare 
access. Thus, the study has good external validity. The study included only those cancer patients 
who survived more than a year and the findings of the sensitivity analyses showed that arthritis 
was not associated with increased risk of developing mood disorders regardless of cancer patients’ 
survival (more vs. less than a year). However, MMB was a significant risk factor for mood 
disorders in patients surviving more than a year and did not affect patients surviving less than a 
year. So, the findings may be more applicable for those patients surviving longer periods.  
     The second part of the thesis was a cohort study that could provide evidence of whether the 
increased HCU in a cancer patient with arthritis and mood disorders was originally related to these 
conditions. We felt that the retrospective cohort design was appropriate and feasible for this study 
as we could look at the average HCU per person-year over an extended period of time at the 
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population level and establish a temporal association between arthritis, mood disorders, and HCU 
in cancer patients. Although there was some misclassification of exposure as described above, the 
large sample size, and accounting for the time of development of mood disorders and arthritis 
provided some suggestions of the impact of these conditions on the HCU of cancer patients. 
However, a prospective cohort study with the cancer patients diagnosed between a specified period 
and following them for a substantial duration while taking into account the actual time of diagnosis 
of mood disorders and arthritis will allow establishing a stronger causal relationship between the 
chronic conditions, namely arthritis, mood disorders, and health care utilization.   









































      The findings of this population-based study demonstrated that arthritis was not associated 
significantly with mood disorders in cancer patients in Ontario, rather the number of chronic 
conditions significantly increased the risk of developing mood disorders. The study also showed 
that arthritis and mood disorders increased HCU in cancer patients and mood disorders had a more 
profound impact. Arthritis alone increased only ED visits per person-year while decreasing 
hospitalization. On the contrary, mood disorders increased both hospitalization and ED visits per 
person-year. The impact of arthritis and mood disorders on the HCU of cancer patients was most 
in the absence of any other comorbidities.  
     MMB is common among cancer patients and around 75% of the patients in Ontario had at least 
one co-occurring condition (Koné Pefoyo et al., 2015). Addressing MMB in cancer patients is the 
key to decrease the risk of developing psychological conditions including mood disorders. 
Depression plays an important role in cancer treatment and outcome. It leads to decreased survival, 
complicacy in cancer management, and lower quality of life. Identifying cancer patients more 
prone to develop depression and early screening for the condition will improve cancer management 
and outcome. Moreover, mood disorders and arthritis increased HCU in cancer patients posing a 
burden to the health care system. If patients with mood disorders are detected early in the course 
of the disease, the management of their condition will be less resource-oriented.  
     Appropriate care management in cancer patients is crucial and is challenged by psychiatric 
disorders. We identified the combined effect of arthritis and mood disorders on increasing 
hospitalizations or emergency visits among cancer patients. It is a challenge for the health care 
system to accommodate complex cancer patients with varied patterns of comorbidities. Identifying 
the impact of arthritis/mood disorders clusters within each multimorbidity level will help in 
approaching patients with higher health care needs. 
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         Our study found no increased risk of mood disorders associated with arthritis in cancer 
patients. However, other chronic conditions may increase the risk of mood disorders in these 
patients. Future research should be oriented to find out the comorbidities having the highest impact 
on the mental health of cancer patients. Research regarding individual chronic conditions, MMB, 
and cancer outcomes like survival and management should be encouraged. We found that the 
combination of arthritis and mood disorders increased HCU in cancer patients. There should be 
other clusters of chronic conditions impacting HCU in cancer patients. The future endeavor can be 
made to identify the disease clusters withing each MMB level causing the highest HCU in order 
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Model Diagnostic for Negative Binomial Model Showing the Adjusted Impact of Mood 
Disorders and Arthritis on the Average Annual Hospitalizations of Cancer Patients 
Including the Interaction Between Cancer and Multimorbidity 
 
Criteria For Assessing Goodness Of Fit 
Criterion DF Value Value/DF 
Deviance 45E4 292838.3925 0.6543 
Scaled Deviance 45E4 292838.3925 0.6543 
Pearson Chi-Square 45E4 457534.5635 1.0223 
Scaled Pearson X2 45E4 457534.5635 1.0223 
Log Likelihood   -356063.1591   
Full Log Likelihood   -410172.5910   
AIC (smaller is better)   820485.1821   
AICC (smaller is better)   820485.2043   














Model Diagnostic for Negative Binomial Model Showing the Adjusted Impact of Mood 
Disorders and Arthritis on the Average Annual ED Visits of Cancer Patients Including the 
Interaction Between Cancer and Multimorbidity 
 
Criteria For Assessing Goodness Of Fit 
Criterion DF Value Value/DF 
Deviance 45E4 325038.1235 0.7263 
Scaled Deviance 45E4 325038.1235 0.7263 
Pearson Chi-Square 45E4 594404.4494 1.3281 
Scaled Pearson X2 45E4 594404.4494 1.3281 
Log Likelihood   -375710.6651   
Full Log Likelihood   -487626.0920   
AIC (smaller is better)   975392.1840   
AICC (smaller is better)   975392.2062   
BIC (smaller is better)   976163.0020   
 
